4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
| Title | Journal |
|---|---|
| Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. | Toxicology letters 20181001 |
| Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. | Toxicology in vitro : an international journal published in association with BIBRA 20180901 |
| Flavan enantiomers from Daphne giraldii selectively induce apoptotic cell death in p53-null hepatocarcinoma cells in vitro. | Chemico-biological interactions 20180601 |
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet (London, England) 20180324 |
| Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. | Toxicology 20180215 |
| Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. | The Journal of biological chemistry 20170908 |
| Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. | Toxicology in vitro : an international journal published in association with BIBRA 20160301 |
| Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. | BMC nephrology 20160101 |
| New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. | Nutrition and cancer 20160101 |
| Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. | Oncotarget 20150929 |
| Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20150401 |
| Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. | Toxicological sciences : an official journal of the Society of Toxicology 20150201 |
| Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity. | Chemical research in toxicology 20150120 |
| Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. | Molecular cancer therapeutics 20140401 |
| Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. | Toxicology and applied pharmacology 20140115 |
| Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. | Cancer chemotherapy and pharmacology 20130501 |
| Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501 |
| Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. | Cancer letters 20130201 |
| Targeted agents and systemic therapy in hepatocellular carcinoma. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20130101 |
| The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. | PloS one 20130101 |
| EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. | International journal of cancer 20121215 |
| Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. | Investigational new drugs 20121201 |
| Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. | Investigational new drugs 20121201 |
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. | Investigational new drugs 20121201 |
| Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. | Medical oncology (Northwood, London, England) 20121201 |
| Extrahepatic spread of hepatocellular carcinoma. | Panminerva medica 20121201 |
| Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. | Molecular pharmaceutics 20121105 |
| The effects of sorafenib on liver regeneration in a model of partial hepatectomy. | The Journal of surgical research 20121101 |
| Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. | Pediatric blood & cancer 20121101 |
| The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. | Cancer 20121101 |
| A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. | Annals of surgical oncology 20121101 |
| The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. | Haematologica 20121101 |
| BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20121101 |
| MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20121101 |
| Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20121101 |
| Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. | Journal of hepatology 20121101 |
| Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20121101 |
| High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. | Transplant international : official journal of the European Society for Organ Transplantation 20121101 |
| Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. | European journal of endocrinology 20121101 |
| Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. | International journal of oncology 20121101 |
| Design, synthesis and biological activities of sorafenib derivatives as antitumor agents. | Bioorganic & medicinal chemistry letters 20121101 |
| Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20121101 |
| A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3. | Haematologica 20121101 |
| Ontogeny and sorafenib metabolism. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Saturable absorption of sorafenib in patients with solid tumors: a population model. | Investigational new drugs 20121001 |
| Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. | Investigational new drugs 20121001 |
| Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. | Investigational new drugs 20121001 |
| Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. | Pediatric blood & cancer 20121001 |
| Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. | Pediatric blood & cancer 20121001 |
| Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors. | Clinical and experimental dermatology 20121001 |
| Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? | International journal of urology : official journal of the Japanese Urological Association 20121001 |
| Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20121001 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. | Journal of hepatology 20121001 |
| Sorafenib for lung cancer: is the 'Battle' still open? | Expert opinion on investigational drugs 20121001 |
| Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20121001 |
| Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. | Molecular cancer therapeutics 20121001 |
| The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. | Acta pharmacologica Sinica 20121001 |
| Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. | The Annals of pharmacotherapy 20121001 |
| Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. | Hepatobiliary & pancreatic diseases international : HBPD INT 20121001 |
| Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. | Cancer letters 20120928 |
| An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. | Biochemical and biophysical research communications 20120928 |
| A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma. | International journal of cardiology 20120920 |
| Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. | The Journal of biological chemistry 20120914 |
| FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. | Cell stem cell 20120907 |
| Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. | European journal of radiology 20120901 |
| Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2. | Medical oncology (Northwood, London, England) 20120901 |
| Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? | Medical oncology (Northwood, London, England) 20120901 |
| Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. | Urologic oncology 20120901 |
| Sorafenib rechallenge in patients with metastatic renal cell carcinoma. | BJU international 20120901 |
| Sorafenib rechalenge in metastatic renal cell carcinoma. | BJU international 20120901 |
| K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. | Cancer letters 20120901 |
| Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. | BJU international 20120901 |
| Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. | Journal of gastroenterology 20120901 |
| Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. | Retina (Philadelphia, Pa.) 20120901 |
| A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. | Clinical genitourinary cancer 20120901 |
| Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120901 |
| Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. | Journal of hepatology 20120901 |
| Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. | Carcinogenesis 20120901 |
| Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. | Nuclear medicine communications 20120901 |
| Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. | The Journal of clinical endocrinology and metabolism 20120901 |
| Sorafenib in non-small cell lung cancer. | Expert opinion on investigational drugs 20120901 |
| Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. | The oncologist 20120901 |
| Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120901 |
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120901 |
| Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. | European journal of medicinal chemistry 20120901 |
| Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. | Zeitschrift fur Gastroenterologie 20120901 |
| Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? | Transplantation proceedings 20120901 |
| Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. | Anticancer research 20120901 |
| Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. | Cancer journal (Sudbury, Mass.) 20120901 |
| [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. | Magyar onkologia 20120901 |
| Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. | Clinics (Sao Paulo, Brazil) 20120901 |
| Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). | Clinical drug investigation 20120808 |
| Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. | Clinical drug investigation 20120808 |
| Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. | British journal of cancer 20120807 |
| Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. | Investigational new drugs 20120801 |
| Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. | Investigational new drugs 20120801 |
| SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. | Investigational new drugs 20120801 |
| A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. | Investigational new drugs 20120801 |
| Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells. | Investigational new drugs 20120801 |
| Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | International journal of cancer 20120801 |
| Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. | Critical reviews in oncology/hematology 20120801 |
| Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20120801 |
| PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. | The Journal of surgical research 20120801 |
| Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. | Cornea 20120801 |
| New use for an old drug: inhibiting ABCG2 with sorafenib. | Molecular cancer therapeutics 20120801 |
| Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. | The Journal of pathology 20120801 |
| Sorafenib in locally advanced or metastatic breast cancer. | Expert opinion on investigational drugs 20120801 |
| Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120801 |
| Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. | International journal of oncology 20120801 |
| Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. | Molecular cancer therapeutics 20120801 |
| Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. | Endocrine-related cancer 20120801 |
| Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. | British journal of haematology 20120801 |
| Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. | Cancer chemotherapy and pharmacology 20120801 |
| Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. | Thyroid : official journal of the American Thyroid Association 20120801 |
| Molecular mechanisms of sorafenib action in liver cancer cells. | Cell cycle (Georgetown, Tex.) 20120801 |
| Targeting angiogenesis in metastatic breast cancer. | The oncologist 20120801 |
| HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. | Anticancer research 20120801 |
| Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120801 |
| Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension. | American journal of respiratory and critical care medicine 20120801 |
| [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20120801 |
| The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. | Future oncology (London, England) 20120801 |
| Impact of restricting access to high-cost medications for hepatocellular carcinoma. | Expert review of pharmacoeconomics & outcomes research 20120801 |
| [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. | Hinyokika kiyo. Acta urologica Japonica 20120801 |
| Sorafenib in advanced melanoma: a critical role for pharmacokinetics? | British journal of cancer 20120724 |
| Preliminary experience with personalized and targeted therapy for pediatric brain tumors. | Pediatric blood & cancer 20120715 |
| Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. | Biochemical pharmacology 20120715 |
| Combining antiangiogenics to overcome resistance: rationale and clinical experience. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120715 |
| Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. | Bioorganic & medicinal chemistry 20120715 |
| GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). | Biochemical and biophysical research communications 20120706 |
| Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. | European journal of radiology 20120701 |
| Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. | Journal of cellular and molecular medicine 20120701 |
| Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. | The Journal of surgical research 20120701 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. | European journal of cancer (Oxford, England : 1990) 20120701 |
| Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. | Cancer letters 20120701 |
| Targeted therapy for biliary tract cancers. | Journal of hepato-biliary-pancreatic sciences 20120701 |
| Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. | Hepatology (Baltimore, Md.) 20120701 |
| Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. | Leukemia 20120701 |
| A maxillary mass in a HBV-cirrhotic patient. | Liver international : official journal of the International Association for the Study of the Liver 20120701 |
| Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | Journal of hepatology 20120701 |
| Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | Journal of hepatology 20120701 |
| 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines. | European journal of medicinal chemistry 20120701 |
| Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. | Scandinavian journal of gastroenterology 20120701 |
| RAIN-Droplet: a novel 3D in vitro angiogenesis model. | Laboratory investigation; a journal of technical methods and pathology 20120701 |
| Phase II study of sorafenib in patients with relapsed or refractory lymphoma. | British journal of haematology 20120701 |
| Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. | Cancer biology & therapy 20120701 |
| First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. | International journal of clinical practice 20120701 |
| Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. | Journal of vascular and interventional radiology : JVIR 20120701 |
| The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. | Anticancer research 20120701 |
| [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120701 |
| Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. | Cell death & disease 20120701 |
| Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? | Expert review of anticancer therapy 20120701 |
| Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. | Acta medica Indonesiana 20120701 |
| Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. | Journal of medicinal chemistry 20120628 |
| Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. | Blood 20120621 |
| Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120615 |
| Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo. | Biochemical and biophysical research communications 20120615 |
| Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. | Nature 20120606 |
| Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. | British journal of cancer 20120605 |
| Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. | British journal of cancer 20120605 |
| Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. | Journal of gastrointestinal cancer 20120601 |
| Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. | Investigational new drugs 20120601 |
| Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. | Investigational new drugs 20120601 |
| Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. | Medical oncology (Northwood, London, England) 20120601 |
| A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. | Investigational new drugs 20120601 |
| Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. | Medical oncology (Northwood, London, England) 20120601 |
| Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. | Hematological oncology 20120601 |
| Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. | Bone marrow transplantation 20120601 |
| Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. | Critical reviews in oncology/hematology 20120601 |
| Sorafenib in hepatocellular carcinoma - a post marketing evaluation. | Immunopharmacology and immunotoxicology 20120601 |
| Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. | Leukemia & lymphoma 20120601 |
| Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20120601 |
| Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. | Leukemia 20120601 |
| Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. | European radiology 20120601 |
| Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report. | Clinical genitourinary cancer 20120601 |
| Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. | Cancer letters 20120601 |
| Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. | Clinical and experimental nephrology 20120601 |
| Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. | Journal of hepatology 20120601 |
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Journal of hepatology 20120601 |
| Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. | Journal of hepatology 20120601 |
| Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. | Journal of cancer research and clinical oncology 20120601 |
| Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. | Anti-cancer drugs 20120601 |
| Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. | Endocrine-related cancer 20120601 |
| TACE with or without systemic therapy? | Journal of hepatology 20120601 |
| Management of hepatocellular carcinoma: beyond sorafenib. | Current oncology reports 20120601 |
| Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. | Cell biochemistry and biophysics 20120601 |
| Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis. | Asia-Pacific journal of clinical oncology 20120601 |
| The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. | Asia-Pacific journal of clinical oncology 20120601 |
| Multiple cutaneous metastatic chordomas from the sacrum. | Journal of the American Academy of Dermatology 20120601 |
| Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. | Clinical genitourinary cancer 20120601 |
| Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. | Medical ultrasonography 20120601 |
| [A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120601 |
| Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. | Archives of dermatology 20120601 |
| The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. | Neoplasia (New York, N.Y.) 20120601 |
| [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20120601 |
| Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. | Blood 20120531 |
| Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. | The EMBO journal 20120530 |
| Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. | American journal of physiology. Gastrointestinal and liver physiology 20120515 |
| [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. | Zhonghua yi xue za zhi 20120515 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. | BJU international 20120501 |
| Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. | Annals of surgical oncology 20120501 |
| Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. | Journal of clinical pharmacology 20120501 |
| Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. | Journal of hepatology 20120501 |
| Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120501 |
| MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. | British journal of haematology 20120501 |
| Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). | Oncology reports 20120501 |
| Targeted therapeutic strategies for the management of renal cell carcinoma. | Current opinion in oncology 20120501 |
| Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. | European journal of cancer (Oxford, England : 1990) 20120501 |
| Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. | Cancer biology & therapy 20120501 |
| Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. | Cancer biology & therapy 20120501 |
| Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120501 |
| Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20120501 |
| Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. | Thyroid : official journal of the American Thyroid Association 20120501 |
| Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. | Radiology 20120501 |
| Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. | Clinical and experimental pharmacology & physiology 20120501 |
| Sorafenib for treatment of hepatocellular carcinoma: a systematic review. | Digestive diseases and sciences 20120501 |
| Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. | Bioorganic & medicinal chemistry 20120501 |
| Sorafenib in liver cancer. | Expert opinion on pharmacotherapy 20120501 |
| [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)]. | Der Urologe. Ausg. A 20120501 |
| Painful leg mass. | The Journal of family practice 20120501 |
| Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. | Future oncology (London, England) 20120501 |
| Resampling phase III data to assess phase II trial designs and endpoints. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120415 |
| Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120415 |
| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. | Cell 20120413 |
| [Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. | Zhonghua yi xue za zhi 20120403 |
| The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. | Investigational new drugs 20120401 |
| Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. | Journal of cellular physiology 20120401 |
| Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. | European journal of oncology nursing : the official journal of European Oncology Nursing Society 20120401 |
| Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. | Pediatric blood & cancer 20120401 |
| Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. | Liver international : official journal of the International Association for the Study of the Liver 20120401 |
| Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. | Journal of cancer research and clinical oncology 20120401 |
| Sorafenib in metastatic thyroid cancer. | Endocrine-related cancer 20120401 |
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120401 |
| Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. | Cancer biology & therapy 20120401 |
| Intracranial metastasis from pediatric GI stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401 |
| Sorafenib in melanoma. | Expert opinion on investigational drugs 20120401 |
| Molecular targeted therapy in acute myeloid leukemia. | Hematology (Amsterdam, Netherlands) 20120401 |
| Hepatocellular carcinoma. | Lancet (London, England) 20120331 |
| Indian health groups welcome country's first compulsory licence. | BMJ (Clinical research ed.) 20120316 |
| Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310 |
| Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. | Molecular pharmaceutics 20120305 |
| Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. | Journal of proteome research 20120302 |
| A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib. | Journal of gastrointestinal cancer 20120301 |
| Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120301 |
| Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? | Journal of hepatology 20120301 |
| Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. | Cancer chemotherapy and pharmacology 20120301 |
| [Renal tolerance of targeted therapies]. | Bulletin du cancer 20120301 |
| Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. | Clinical genitourinary cancer 20120301 |
| Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. | Journal of gastroenterology 20120301 |
| Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. | European journal of endocrinology 20120301 |
| Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. | American journal of hematology 20120301 |
| Objective response to sorafenib in advanced clear-cell sarcoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20120301 |
| Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. | European journal of cancer (Oxford, England : 1990) 20120301 |
| Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. | Annals of oncology : official journal of the European Society for Medical Oncology 20120301 |
| Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301 |
| Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. | The oncologist 20120301 |
| Using NF-κB as a molecular target for theranostics in radiation oncology research. | Expert review of molecular diagnostics 20120301 |
| [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. | Magyar onkologia 20120301 |
| Advanced HCC: emerging molecular therapies. | Minerva gastroenterologica e dietologica 20120301 |
| LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. | PLoS genetics 20120301 |
| Developments in metastatic pancreatic cancer: is gemcitabine still the standard? | World journal of gastroenterology 20120227 |
| Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis. | Biochemical and biophysical research communications 20120217 |
| Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120215 |
| Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). | Clinical cancer research : an official journal of the American Association for Cancer Research 20120215 |
| Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210 |
| Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. | Investigational new drugs 20120201 |
| Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. | Investigational new drugs 20120201 |
| Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. | Investigational new drugs 20120201 |
| Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. | Pediatric blood & cancer 20120201 |
| A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. | Annals of oncology : official journal of the European Society for Medical Oncology 20120201 |
| Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. | Annals of oncology : official journal of the European Society for Medical Oncology 20120201 |
| Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. | Molecular biology reports 20120201 |
| [KIT and KIT: from biology to clinical use]. | Bulletin du cancer 20120201 |
| Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. | Cancer chemotherapy and pharmacology 20120201 |
| Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. | Cancer 20120201 |
| [Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma]. | Actas urologicas espanolas 20120201 |
| Anti-angiogenic therapy: concept to clinic. | Microcirculation (New York, N.Y. : 1994) 20120201 |
| Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. | Endocrine-related cancer 20120201 |
| Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. | Molecular cancer therapeutics 20120201 |
| Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. | Molecular cancer therapeutics 20120201 |
| Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. | Clinical and experimental immunology 20120201 |
| [Hepatocellular carcinoma: what's new?]. | Deutsche medizinische Wochenschrift (1946) 20120201 |
| Sorafenib for the treatment of renal cancer. | Expert opinion on pharmacotherapy 20120201 |
| Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120201 |
| Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. | AJR. American journal of roentgenology 20120201 |
| Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). | The oncologist 20120201 |
| Phase II studies in soft tissue sarcoma: time for reappraisal. | The oncologist 20120201 |
| Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. | Anticancer research 20120201 |
| Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. | Anticancer research 20120201 |
| [Sorafenib and octreotide combination therapy can inhibit proliferation of and induce apoptosis in human hepatoma cells]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20120201 |
| New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation. | Molecules (Basel, Switzerland) 20120123 |
| RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120 |
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies. | Journal of the National Cancer Institute 20120118 |
| Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. | Cancer cell 20120117 |
| [Endocrinology]. | Revue medicale suisse 20120111 |
| An update on targeted therapy in metastatic renal cell carcinoma. | Urologic oncology 20120101 |
| Functional analysis of microRNAs in human hepatocellular cancer stem cells. | Journal of cellular and molecular medicine 20120101 |
| A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20120101 |
| A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. | Cancer chemotherapy and pharmacology 20120101 |
| Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. | Cancer 20120101 |
| Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma. | Pediatric blood & cancer 20120101 |
| Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? | Journal of surgical oncology 20120101 |
| Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. | Leukemia 20120101 |
| [Long-standing differentiated thyroid carcinoma]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101 |
| Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. | Journal of biochemistry 20120101 |
| Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20120101 |
| Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. | Investigative radiology 20120101 |
| Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). | Molecular medicine (Cambridge, Mass.) 20120101 |
| The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. | Leukemia research 20120101 |
| The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. | Alimentary pharmacology & therapeutics 20120101 |
| Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120101 |
| Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib. | Urologia internationalis 20120101 |
| Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors. | International journal of clinical pharmacology and therapeutics 20120101 |
| Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. | BJU international 20120101 |
| Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. | Current medicinal chemistry 20120101 |
| Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. | Cell death & disease 20120101 |
| Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. | World journal of surgical oncology 20120101 |
| Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). | PloS one 20120101 |
| Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. | Oncology 20120101 |
| Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. | World journal of surgical oncology 20120101 |
| Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. | BMC cancer 20120101 |
| Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. | Clinical & developmental immunology 20120101 |
| Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. | PloS one 20120101 |
| A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. | Oncology 20120101 |
| Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. | Tumori 20120101 |
| The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines. | Chemotherapy 20120101 |
| Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. | BMC cancer 20120101 |
| Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20120101 |
| The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. | BMC cancer 20120101 |
| Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. | In vivo (Athens, Greece) 20120101 |
| The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. | Clinical laboratory 20120101 |
| Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. | International journal of nanomedicine 20120101 |
| Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. | Oncology 20120101 |
| Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. | Onkologie 20120101 |
| Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. | Oncology 20120101 |
| Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. | PloS one 20120101 |
| [Hepatocellular carcinoma - long-term treatable disease]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101 |
| Hypothyroidism during treatment with tyrosine kinase inhibitors. | Endokrynologia Polska 20120101 |
| State of the art of the therapeutic perspective of sorafenib against hematological malignancies. | Current medicinal chemistry 20120101 |
| Clinicopathological characteristics of hepatocellular carcinoma in Turkey. | Asian Pacific journal of cancer prevention : APJCP 20120101 |
| Affinity purification of protein kinases that adopt a specific inactive conformation. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. | BMC cancer 20120101 |
| Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. | Current topics in medicinal chemistry 20120101 |
| Sorafenib-induced tuberculosis reactivation. | Onkologie 20120101 |
| [Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL]. | Biofizika 20120101 |
| Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner. | BMC cancer 20120101 |
| Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. | International journal of molecular sciences 20120101 |
| Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase. | Journal of chemical information and modeling 20111227 |
| Role of BRAF in thyroid oncogenesis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111215 |
| A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. | Circulation research 20111209 |
| Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. | British journal of cancer 20111206 |
| Tilting the AXIS towards therapeutic limits in renal cancer. | Lancet (London, England) 20111203 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Lancet (London, England) 20111203 |
| Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. | Investigational new drugs 20111201 |
| Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. | Medical oncology (Northwood, London, England) 20111201 |
| Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. | Medical oncology (Northwood, London, England) 20111201 |
| Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. | Medical oncology (Northwood, London, England) 20111201 |
| Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. | Investigational new drugs 20111201 |
| Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. | Medical oncology (Northwood, London, England) 20111201 |
| Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. | Medical oncology (Northwood, London, England) 20111201 |
| Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. | World journal of urology 20111201 |
| Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. | Journal of clinical pharmacology 20111201 |
| Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. | BJU international 20111201 |
| Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. | Cancer chemotherapy and pharmacology 20111201 |
| Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. | Pharmaceutical research 20111201 |
| Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111201 |
| Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. | European urology 20111201 |
| Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. | Journal of clinical immunology 20111201 |
| Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. | Hepatology (Baltimore, Md.) 20111201 |
| Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. | Neuro-oncology 20111201 |
| Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. | Gynecologic oncology 20111201 |
| Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors. | Bioorganic & medicinal chemistry letters 20111201 |
| New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies. | European journal of medicinal chemistry 20111201 |
| Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. | Expert review of anticancer therapy 20111201 |
| Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? | Experimental dermatology 20111201 |
| A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. | Therapeutic drug monitoring 20111201 |
| Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111201 |
| Erythema multiforme-like drug reaction to sorafenib. | Journal of drugs in dermatology : JDD 20111201 |
| The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). | The oncologist 20111201 |
| Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. | Journal of Korean medical science 20111201 |
| VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20111201 |
| Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. | Medical molecular morphology 20111201 |
| Sorafenib: muscle wasting. | Prescrire international 20111201 |
| Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. | British journal of cancer 20111122 |
| Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. | European journal of pharmacology 20111116 |
| Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111115 |
| HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. | Breast cancer research and treatment 20111101 |
| Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. | Cancer chemotherapy and pharmacology 20111101 |
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. | Journal of hepatology 20111101 |
| Sorafenib in renal cell carcinoma. | Critical reviews in oncology/hematology 20111101 |
| Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. | Cancer chemotherapy and pharmacology 20111101 |
| Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. | Cancer 20111101 |
| BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. | British journal of haematology 20111101 |
| Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. | Journal of gastroenterology and hepatology 20111101 |
| Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. | Lung cancer (Amsterdam, Netherlands) 20111101 |
| Targeting STAT3 in hepatocellular carcinoma: sorafenib again…. | Journal of hepatology 20111101 |
| Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101 |
| Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. | Cancer biology & therapy 20111101 |
| Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. | Current cancer drug targets 20111101 |
| A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. | European journal of gastroenterology & hepatology 20111101 |
| Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line. | Archiv der Pharmazie 20111101 |
| Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. | Alimentary pharmacology & therapeutics 20111101 |
| Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. | Japanese journal of clinical oncology 20111101 |
| Clinical experience with antiangiogenic therapy in leukemia. | Current cancer drug targets 20111101 |
| The two faces of FBW7 in cancer drug resistance. | BioEssays : news and reviews in molecular, cellular and developmental biology 20111101 |
| Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma? | Journal of gastroenterology and hepatology 20111101 |
| Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20111101 |
| Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. | The oncologist 20111101 |
| Role of sorafenib in renal cell carcinoma: focus on elderly patients. | Expert review of anticancer therapy 20111101 |
| Chloracne-like drug eruption associated with sorafenib. | Journal of drugs in dermatology : JDD 20111101 |
| Tyrosine kinase inhibitors for metastatic renal cell carcinoma. | Drug and therapeutics bulletin 20111101 |
| Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. | Anticancer research 20111101 |
| [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. | International journal of pharmaceutics 20111031 |
| Reversible cardiomyopathy associated with sunitinib and sorafenib. | The New England journal of medicine 20111027 |
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111020 |
| Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. | Human molecular genetics 20111015 |
| A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. | Investigational new drugs 20111001 |
| Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. | Investigational new drugs 20111001 |
| Ultraviolet recall dermatitis reaction with sorafenib. | Investigational new drugs 20111001 |
| A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. | American journal of clinical oncology 20111001 |
| Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. | Journal of hepatology 20111001 |
| Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. | American journal of respiratory cell and molecular biology 20111001 |
| Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. | BJU international 20111001 |
| Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. | Autophagy 20111001 |
| [Targeting the RAS signalling pathway in cancer]. | Bulletin du cancer 20111001 |
| Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. | Gynecologic oncology 20111001 |
| Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. | The Journal of investigative dermatology 20111001 |
| Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. | PharmacoEconomics 20111001 |
| Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. | Transplant international : official journal of the European Society for Organ Transplantation 20111001 |
| Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. | Autophagy 20111001 |
| The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. | The Journal of clinical endocrinology and metabolism 20111001 |
| Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. | Current cancer drug targets 20111001 |
| Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. | Alimentary pharmacology & therapeutics 20111001 |
| [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. | Bulletin du cancer 20111001 |
| [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. | Gastroenterologia y hepatologia 20111001 |
| Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways. | Anticancer research 20111001 |
| [Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)]. | Der Urologe. Ausg. A 20111001 |
| [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111001 |
| [Dermatologic side effects induced by new angiogenesis inhibitors]. | Bulletin du cancer 20111001 |
| [Myocardial metastasis from renal cell carcinoma treated with sorafenib]. | Hinyokika kiyo. Acta urologica Japonica 20111001 |
| A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. | Cancer 20110915 |
| c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. | Cancer biology & therapy 20110915 |
| Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. | World journal of gastroenterology 20110914 |
| Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901 |
| Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. | Journal of clinical gastroenterology 20110901 |
| Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. | BJU international 20110901 |
| Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. | Journal of cancer survivorship : research and practice 20110901 |
| [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. | Der Urologe. Ausg. A 20110901 |
| Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. | American journal of physiology. Cell physiology 20110901 |
| t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. | Leukemia research 20110901 |
| Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20110901 |
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. | European journal of cancer (Oxford, England : 1990) 20110901 |
| Targeted-therapy and imaging response: a new paradigm for clinical evaluation? | Reviews on recent clinical trials 20110901 |
| Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. | Liver international : official journal of the International Association for the Study of the Liver 20110901 |
| Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. | The FEBS journal 20110901 |
| The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. | The oncologist 20110901 |
| Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports. | Transplantation proceedings 20110901 |
| Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110901 |
| Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. | Medical molecular morphology 20110901 |
| Interstitial granulomatous drug reaction to sorafenib. | Archives of dermatology 20110901 |
| [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110901 |
| Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. | Histopathology 20110901 |
| [Synthesis and biological evaluation of sorafenib thiourea derivatives]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110901 |
| Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. | Blood 20110825 |
| Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820 |
| Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110815 |
| Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110815 |
| Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| Population pharmacokinetic analysis of sorafenib in patients with solid tumours. | British journal of clinical pharmacology 20110801 |
| Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. | The British journal of dermatology 20110801 |
| Classic biphasic pulmonary blastoma: a case report and review of the literature. | Lung cancer (Amsterdam, Netherlands) 20110801 |
| In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. | Endocrine-related cancer 20110801 |
| Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. | European journal of endocrinology 20110801 |
| Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. | International journal of oncology 20110801 |
| Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. | Hepatology (Baltimore, Md.) 20110801 |
| Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. | European journal of medicinal chemistry 20110801 |
| PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. | Cancer chemotherapy and pharmacology 20110801 |
| Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. | European journal of cancer (Oxford, England : 1990) 20110801 |
| Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. | Biochemical pharmacology 20110801 |
| An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. | Expert opinion on investigational drugs 20110801 |
| cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. | Toxicological sciences : an official journal of the Society of Toxicology 20110801 |
| Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. | Cancer biology & therapy 20110801 |
| Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. | Cancer biology & therapy 20110801 |
| Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. | Cancer investigation 20110801 |
| Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. | Cancer investigation 20110801 |
| Sorafenib-induced eruption resembling pityriasis rubra pilaris. | Journal of the American Academy of Dermatology 20110801 |
| Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. | Hematology/oncology clinics of North America 20110801 |
| Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. | Hematology/oncology clinics of North America 20110801 |
| Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. | Clinical lymphoma, myeloma & leukemia 20110801 |
| [Systemic treatment of renal cell carcinoma - recent update]. | Wiener medizinische Wochenschrift (1946) 20110801 |
| An approach to meta-analysis of dose-finding studies. | Statistics in medicine 20110730 |
| [Adverse effects of new oncologic therapies]. | Praxis 20110727 |
| Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. | British journal of cancer 20110726 |
| Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. | British journal of cancer 20110726 |
| Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. | International journal of cancer 20110715 |
| The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. | Biochemical pharmacology 20110715 |
| Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. | Cancer research 20110715 |
| Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). | Bioorganic & medicinal chemistry 20110715 |
| Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. | Cancer chemotherapy and pharmacology 20110701 |
| High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. | Cancer chemotherapy and pharmacology 20110701 |
| Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20110701 |
| Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20110701 |
| Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20110701 |
| Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. | Leukemia 20110701 |
| Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. | European journal of medicinal chemistry 20110701 |
| FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. | International journal of oncology 20110701 |
| One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. | European journal of cancer (Oxford, England : 1990) 20110701 |
| Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. | Molecular cancer therapeutics 20110701 |
| Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma. | Journal of pediatric hematology/oncology 20110701 |
| Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. | Anti-cancer agents in medicinal chemistry 20110701 |
| An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. | Expert opinion on pharmacotherapy 20110701 |
| The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. | Alimentary pharmacology & therapeutics 20110701 |
| Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110701 |
| Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110701 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20110701 |
| Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. | Clinical lung cancer 20110701 |
| Pancreatic endocrine tumors: a report on a patient treated with sorafenib. | Journal of Korean medical science 20110701 |
| microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. | FEBS letters 20110623 |
| Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620 |
| Activity of Sorafenib against desmoid tumor/deep fibromatosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. | Journal of the National Cancer Institute 20110608 |
| Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. | Investigational new drugs 20110601 |
| Painless acute pancreatitis associated with sorafenib treatment: a case report. | Medical oncology (Northwood, London, England) 20110601 |
| Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor. | International journal of clinical oncology 20110601 |
| Assessment of the treatment response of HCC. | Abdominal imaging 20110601 |
| Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. | Journal of gastroenterology 20110601 |
| Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. | Cancer immunology, immunotherapy : CII 20110601 |
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. | Molecular therapy : the journal of the American Society of Gene Therapy 20110601 |
| Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents. | Archiv der Pharmazie 20110601 |
| Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. | World journal of urology 20110601 |
| Treatment of metastatic renal cell carcinoma and renal pelvic cancer. | Clinical and experimental nephrology 20110601 |
| Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20110601 |
| Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | Molecular cancer therapeutics 20110601 |
| Meta-analysis of dermatological toxicities associated with sorafenib. | Clinical and experimental dermatology 20110601 |
| Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. | Journal of the American Academy of Dermatology 20110601 |
| Sorafenib-associated multivessel coronary artery vasospasm. | Herz 20110601 |
| Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. | International journal of urology : official journal of the Japanese Urological Association 20110601 |
| [New therapeutic options for advanced thyroid cancer]. | Deutsche medizinische Wochenschrift (1946) 20110601 |
| Targeting angiogenesis in esophagogastric adenocarcinoma. | The oncologist 20110601 |
| [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20110601 |
| Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. | NMR in biomedicine 20110601 |
| Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. | Clinical therapeutics 20110601 |
| Sorafenib for the management of advanced renal cell carcinoma. | Expert review of anticancer therapy 20110601 |
| A painful cranial bulge. | Lancet (London, England) 20110521 |
| Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. | World journal of gastroenterology 20110521 |
| Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| Severe sorafenib-induced hand-foot skin reaction. | Dermatology online journal 20110515 |
| Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. | World journal of gastroenterology 20110507 |
| Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. | Cancer treatment reviews 20110501 |
| Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. | Journal of cancer research and clinical oncology 20110501 |
| Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. | Angiogenesis 20110501 |
| [Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium]. | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20110501 |
| Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. | Leukemia 20110501 |
| Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. | European urology 20110501 |
| Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. | Hepatology (Baltimore, Md.) 20110501 |
| Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. | Japanese journal of clinical oncology 20110501 |
| Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. | Liver international : official journal of the International Association for the Study of the Liver 20110501 |
| [Indications and current development of new targeted therapies in pediatric oncology]. | Bulletin du cancer 20110501 |
| [Sorafenib in the treatment of hepatocellular carcinoma]. | Vnitrni lekarstvi 20110501 |
| [News on melanoma from the 2010 Dermatology Days in Paris]. | Annales de dermatologie et de venereologie 20110501 |
| [Progression of sorafenib in the treatment of acute myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110501 |
| [Novelties in the treatment for advanced renal-cell cancer]. | Orvosi hetilap 20110424 |
| Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420 |
| B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger. | The Journal of biological chemistry 20110415 |
| [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. | Bioorganic & medicinal chemistry letters 20110415 |
| Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. | British journal of cancer 20110412 |
| Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. | Molecular pharmaceutics 20110404 |
| Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. | American journal of clinical oncology 20110401 |
| Experience with sorafenib and adverse event management. | Critical reviews in oncology/hematology 20110401 |
| A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. | Cancer chemotherapy and pharmacology 20110401 |
| Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. | Annals of hematology 20110401 |
| A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. | BJU international 20110401 |
| Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. | Breast (Edinburgh, Scotland) 20110401 |
| Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. | Pharmacological research 20110401 |
| Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. | The Journal of pharmacology and experimental therapeutics 20110401 |
| Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20110401 |
| Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. | Urology 20110401 |
| Biomarkers in renal cell carcinoma: what next? | Current oncology reports 20110401 |
| Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. | Experimental hematology 20110401 |
| Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. | The Journal of clinical endocrinology and metabolism 20110401 |
| Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. | Urology 20110401 |
| Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. | Annals of oncology : official journal of the European Society for Medical Oncology 20110401 |
| Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. | Laboratory investigation; a journal of technical methods and pathology 20110401 |
| Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20110401 |
| Sorafenib-induced premalignant and malignant skin lesions. | International journal of dermatology 20110401 |
| Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110401 |
| [Treatment of metastatic renal cell carcinoma]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401 |
| [Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway]. | Zhongguo shi yan xue ye xue za zhi 20110401 |
| Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. | Cell death & disease 20110401 |
| A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. | Clinical advances in hematology & oncology : H&O 20110401 |
| Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib. | Clinical advances in hematology & oncology : H&O 20110401 |
| Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. | Clinical advances in hematology & oncology : H&O 20110401 |
| FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. | Blood 20110324 |
| [Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20110320 |
| Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. | Bioorganic & medicinal chemistry 20110315 |
| Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. | British journal of cancer 20110315 |
| First-line treatment for advanced pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. | JOP : Journal of the pancreas 20110309 |
| SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. | Nature 20110303 |
| NSCLC drug targets acquire new visibility. | Journal of the National Cancer Institute 20110302 |
| Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. | Journal of gastrointestinal cancer 20110301 |
| The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. | Cellular and molecular life sciences : CMLS 20110301 |
| Rapid response to sorafenib in metastatic medullary thyroid carcinoma. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110301 |
| Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. | Leukemia research 20110301 |
| Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia. | Leukemia research 20110301 |
| Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. | European journal of cancer (Oxford, England : 1990) 20110301 |
| Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110301 |
| Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. | Cancer biology & therapy 20110301 |
| Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. | Radiology 20110301 |
| Sorafenib-associated hand-foot syndrome in Japanese patients. | The Journal of dermatology 20110301 |
| Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. | Clinics and research in hepatology and gastroenterology 20110301 |
| Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. | Journal of drugs in dermatology : JDD 20110301 |
| Management of hepatocellular carcinoma: an update. | Hepatology (Baltimore, Md.) 20110301 |
| [Hepatocellular carcinoma]. | Nihon Geka Gakkai zasshi 20110301 |
| What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. | Oncology (Williston Park, N.Y.) 20110301 |
| Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge? | Oncology (Williston Park, N.Y.) 20110301 |
| Sorafenib for HCC: a pragmatic perspective. | Oncology (Williston Park, N.Y.) 20110301 |
| The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. | Oncogene 20110224 |
| Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma. | JAMA 20110223 |
| Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. | Journal of cellular and molecular medicine 20110201 |
| A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. | Lung cancer (Amsterdam, Netherlands) 20110201 |
| The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. | European radiology 20110201 |
| Hypothyroidism in patients with renal cell carcinoma: blessing or curse? | Cancer 20110201 |
| Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. | Laboratory investigation; a journal of technical methods and pathology 20110201 |
| The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. | The Journal of investigative dermatology 20110201 |
| Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. | Cancer biology & therapy 20110201 |
| mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. | Journal of hepatology 20110201 |
| Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. | Thyroid : official journal of the American Thyroid Association 20110201 |
| Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. | Expert opinion on pharmacotherapy 20110201 |
| Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. | International journal of clinical practice 20110201 |
| [Sorafenib and radiotherapy association for hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110201 |
| Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. | Hepatology (Baltimore, Md.) 20110201 |
| Effect of sorafenib on murine liver regeneration. | Hepatology (Baltimore, Md.) 20110201 |
| Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. | Thyroid : official journal of the American Thyroid Association 20110201 |
| [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110201 |
| [Squamous cell carcinoma in a patient receiving sorafenib]. | Annales de dermatologie et de venereologie 20110201 |
| Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. | The oncologist 20110201 |
| Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. | The oncologist 20110201 |
| Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. | The oncologist 20110201 |
| Sorafenib for advanced hepatocellular carcinoma: a systematic review. | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20110201 |
| [Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. | Bulletin du cancer 20110201 |
| Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. | British journal of haematology 20110201 |
| Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. | Blood 20110120 |
| EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. | Cancer cell 20110118 |
| Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. | World journal of gastroenterology 20110114 |
| Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. | Urologic oncology 20110101 |
| Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. | BJU international 20110101 |
| Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. | Journal of neuro-oncology 20110101 |
| Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. | Biochimica et biophysica acta 20110101 |
| Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. | European journal of cancer (Oxford, England : 1990) 20110101 |
| Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. | Anti-cancer drugs 20110101 |
| Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. | Academic radiology 20110101 |
| Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. | The Journal of clinical endocrinology and metabolism 20110101 |
| The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. | The Journal of pharmacology and experimental therapeutics 20110101 |
| Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. | Haematologica 20110101 |
| Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. | Lung cancer (Amsterdam, Netherlands) 20110101 |
| Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. | Breast cancer research and treatment 20110101 |
| Analysis of phosphoproteomics data. | Methods in molecular biology (Clifton, N.J.) 20110101 |
| The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. | The Journal of urology 20110101 |
| Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110101 |
| Kidney cancer: Does hypothyroidism predict clinical outcome? | Nature reviews. Urology 20110101 |
| Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20110101 |
| Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? | Journal of gastroenterology and hepatology 20110101 |
| Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib. | Nephrology (Carlton, Vic.) 20110101 |
| In pursuit of new anti-angiogenic therapies for cancer treatment. | Frontiers in bioscience (Landmark edition) 20110101 |
| Targeting EGFR in bilio-pancreatic and liver carcinoma. | Frontiers in bioscience (Scholar edition) 20110101 |
| Therapeutic advances in women's cancers. | Frontiers in bioscience (Scholar edition) 20110101 |
| How I manage my patients with hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| Novel molecular therapies in hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20110101 |
| Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer. | Acta crystallographica. Section C, Crystal structure communications 20110101 |
| Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. | Molecular cancer therapeutics 20110101 |
| Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. | Wiener klinische Wochenschrift 20110101 |
| Complete response for advanced liver cancer during sorafenib therapy: case report. | BMC gastroenterology 20110101 |
| Invasive squamous cell carcinoma and sorafenib in a black patient. | Archives of dermatology 20110101 |
| Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. | Indian journal of cancer 20110101 |
| Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. | Anticancer research 20110101 |
| Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. | Digestion 20110101 |
| Cold agglutinin disease in fibrolamellar hepatocellular carcinoma: a rare association with a rare cancer variant. | Annals of Saudi medicine 20110101 |
| Advanced hepatocellular carcinoma. Review of targeted molecular drugs. | Annals of hepatology 20110101 |
| Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. | PloS one 20110101 |
| Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. | Biological & pharmaceutical bulletin 20110101 |
| Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. | Endocrine journal 20110101 |
| [Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110101 |
| Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. | BMC cancer 20110101 |
| [Detection by SPECT-CT scan with (99m)Tc-(V) DMSA of bone metastases in patient with medullary thyroid cancer]. | Revista espanola de medicina nuclear 20110101 |
| Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. | The journal of supportive oncology 20110101 |
| All that glitters: sorafenib. | Internal medicine (Tokyo, Japan) 20110101 |
| Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. | Hepato-gastroenterology 20110101 |
| Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. | PloS one 20110101 |
| Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. | BMC gastroenterology 20110101 |
| Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. | Oncology 20110101 |
| Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. | Oncology 20110101 |
| Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo. | Journal of microencapsulation 20110101 |
| How to manage hypersensitivity reactions to biological agents? | European journal of dermatology : EJD 20110101 |
| Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. | BMC cancer 20110101 |
| Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. | Molecular cancer 20110101 |
| Targeted drug therapies and cancer. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. | Digestive diseases (Basel, Switzerland) 20110101 |
| Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. | Digestive diseases (Basel, Switzerland) 20110101 |
| Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. | Digestive diseases (Basel, Switzerland) 20110101 |
| Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. | BMC cancer 20110101 |
| Psoriasiform skin eruption associated with sorafenib therapy. | Indian journal of dermatology, venereology and leprology 20110101 |
| Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. | Dermatologic therapy 20110101 |
| Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| Sorafenib-induced erythema multiforme: three cases. | European journal of dermatology : EJD 20110101 |
| Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. | Molecular cancer 20110101 |
| AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. | Onkologie 20110101 |
| High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. | Oncology 20110101 |
| Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. | Tumori 20110101 |
| Diagnostic and prognostic molecular markers in hepatocellular carcinoma. | Disease markers 20110101 |
| Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. | Oncology 20110101 |
| Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. | PloS one 20110101 |
| High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. | Journal of translational medicine 20110101 |
| Signaling pathways in hepatocellular carcinoma. | Oncology 20110101 |
| Adjuvant therapy after curative treatment for hepatocellular carcinoma. | Oncology 20110101 |
| Radiotherapeutic strategies in the management of hepatocellular carcinoma. | Oncology 20110101 |
| Multidisciplinary management of nonresectable hepatocellular carcinoma. | Oncology 20110101 |
| Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. | Oncology 20110101 |
| Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. | Oncology 20110101 |
| An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. | Journal of cancer research and therapeutics 20110101 |
| Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. | Acta medica (Hradec Kralove) 20110101 |
| Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report. | Tumori 20110101 |
| Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101 |
| Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. | Cancer biomarkers : section A of Disease markers 20110101 |
| Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. | Cancer biology & therapy 20101215 |
| A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. | Cancer 20101215 |
| Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. | International journal of cancer 20101215 |
| Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. | Investigational new drugs 20101201 |
| Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. | Investigational new drugs 20101201 |
| Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. | Medical oncology (Northwood, London, England) 20101201 |
| Experience with sorafenib and the elderly patient. | Medical oncology (Northwood, London, England) 20101201 |
| Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? | Journal of gastrointestinal cancer 20101201 |
| Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. | BJU international 20101201 |
| Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? | European radiology 20101201 |
| 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 20101201 |
| Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. | Pediatric blood & cancer 20101201 |
| Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. | Japanese journal of clinical oncology 20101201 |
| Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. | Cancer 20101201 |
| Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. | Journal of surgical oncology 20101201 |
| [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. | Gastroenterologia y hepatologia 20101201 |
| Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. | European urology 20101201 |
| Sorafenib: rays of hope in thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20101201 |
| Oncogenic RAF: a brief history of time. | Pigment cell & melanoma research 20101201 |
| Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma. | The Journal of urology 20101201 |
| Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. | Cancer science 20101201 |
| Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. | Acta pharmacologica Sinica 20101201 |
| Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20101201 |
| Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. | Transplantation proceedings 20101201 |
| Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. | Archives of dermatology 20101201 |
| PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. | Anticancer research 20101201 |
| More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. | Anticancer research 20101201 |
| Which treatment modality should we choose for advanced hepatocellular carcinoma? | The Korean journal of hepatology 20101201 |
| Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. | World journal of gastroenterology 20101121 |
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. | JAMA 20101117 |
| Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. | Cancer research 20101115 |
| Synergistic activity of letrozole and sorafenib on breast cancer cells. | Breast cancer research and treatment 20101101 |
| Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | BJU international 20101101 |
| Angiogenesis as a therapeutic target in urothelial carcinoma. | Anti-cancer drugs 20101101 |
| Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. | American journal of physiology. Renal physiology 20101101 |
| Targeting B-Raf as a treatment strategy for polycystic kidney disease. | American journal of physiology. Renal physiology 20101101 |
| Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. | Radiology 20101101 |
| Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101 |
| Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. | Journal of cancer research and clinical oncology 20101101 |
| Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101101 |
| Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101 |
| Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101101 |
| [Multimodality treatment for hepatocellular carcinoma]. | Der Internist 20101101 |
| Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. | Expert opinion on biological therapy 20101101 |
| 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20101101 |
| Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. | The British journal of ophthalmology 20101101 |
| Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. | The oncologist 20101101 |
| Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. | Journal of gastroenterology and hepatology 20101101 |
| A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. | British journal of cancer 20101101 |
| Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. | Neoplasia (New York, N.Y.) 20101101 |
| Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. | Anticancer research 20101101 |
| The therapy of kidney cancer with biomolecular drugs. | Cancer treatment reviews 20101101 |
| [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101101 |
| [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]. | Orvosi hetilap 20101024 |
| Risk of arterial thrombosis not increased by sorafenib or sunitinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020 |
| Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101015 |
| Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. | Blood 20101014 |
| A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. | British journal of cancer 20101012 |
| Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. | Investigational new drugs 20101001 |
| Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. | Cancer chemotherapy and pharmacology 20101001 |
| Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. | International journal of clinical oncology 20101001 |
| A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount. | Leukemia research 20101001 |
| Effect of sorafenib on experimental choroidal neovascularization in the rat. | Clinical & experimental ophthalmology 20101001 |
| Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. | Leukemia research 20101001 |
| The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. | International immunopharmacology 20101001 |
| Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101001 |
| Health-related quality of life and sorafenib. | Hepatology (Baltimore, Md.) 20101001 |
| Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001 |
| A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| [Nonsurgical management of hepatocellular carcinoma]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20101001 |
| The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. | Hepatology (Baltimore, Md.) 20101001 |
| Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. | Oncology reports 20101001 |
| Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. | International journal of dermatology 20101001 |
| Atypical linear toxicodermia by sorafenib. | International journal of dermatology 20101001 |
| Developing better treatments in hepatocellular carcinoma. | Expert review of gastroenterology & hepatology 20101001 |
| [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101001 |
| [Hepatocellular carcinoma]. | Nihon rinsho. Japanese journal of clinical medicine 20101001 |
| [Molecular targeted therapy for renal cell carcinoma and other urological cancers]. | Nihon rinsho. Japanese journal of clinical medicine 20101001 |
| Inherited hepatocellular carcinoma. | Best practice & research. Clinical gastroenterology 20101001 |
| Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma. | Gan to kagaku ryoho. Cancer & chemotherapy 20101001 |
| Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. | The Israel Medical Association journal : IMAJ 20101001 |
| Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. | British journal of cancer 20100907 |
| [Treatment of primary hepatocellular carcinoma]. | Orvosi hetilap 20100905 |
| Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. | Medical oncology (Northwood, London, England) 20100901 |
| Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. | Medical oncology (Northwood, London, England) 20100901 |
| Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. | Annals of oncology : official journal of the European Society for Medical Oncology 20100901 |
| Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. | BJU international 20100901 |
| Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. | European journal of gastroenterology & hepatology 20100901 |
| BRAF as therapeutic target in melanoma. | Biochemical pharmacology 20100901 |
| The hand-foot-syndrome associated with medical tumor therapy - classification and management. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20100901 |
| In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. | Current cancer drug targets 20100901 |
| Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20100901 |
| Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. | European journal of cancer (Oxford, England : 1990) 20100901 |
| Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. | Expert opinion on pharmacotherapy 20100901 |
| Sorafenib and radiation: a promising combination in colorectal cancer. | International journal of radiation oncology, biology, physics 20100901 |
| Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20100901 |
| [Sorafenib]. | Deutsche medizinische Wochenschrift (1946) 20100901 |
| [Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]. | Deutsche medizinische Wochenschrift (1946) 20100901 |
| Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. | Hepatology (Baltimore, Md.) 20100901 |
| Sorafenib-induced destructive thyroiditis. | Thyroid : official journal of the American Thyroid Association 20100901 |
| Transient perforating folliculitis induced by sorafenib. | The Journal of dermatology 20100901 |
| [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100901 |
| Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. | Clinical advances in hematology & oncology : H&O 20100901 |
| [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma]. | Zhonghua yi xue za zhi 20100817 |
| Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. | Journal of medicinal chemistry 20100812 |
| From a cancer drug fund to value based pricing of drugs. | BMJ (Clinical research ed.) 20100812 |
| Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib. | Chinese medical journal 20100805 |
| Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? | European journal of gastroenterology & hepatology 20100801 |
| Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100801 |
| Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. | Annals of oncology : official journal of the European Society for Medical Oncology 20100801 |
| In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. | Drug metabolism and disposition: the biological fate of chemicals 20100801 |
| Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. | Journal of cellular physiology 20100801 |
| Sorafenib plus valproic acid for infant spinal glioblastoma. | Journal of pediatric hematology/oncology 20100801 |
| A case of variant angina in a patient under chronic treatment with sorafenib. | Nature reviews. Clinical oncology 20100801 |
| Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. | The Journal of clinical endocrinology and metabolism 20100801 |
| Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. | Japanese journal of clinical oncology 20100801 |
| Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. | Radiology 20100801 |
| Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. | Leukemia 20100801 |
| A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. | Leukemia 20100801 |
| Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. | Radiology 20100801 |
| ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. | Cancer biology & therapy 20100801 |
| Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. | Cancer 20100801 |
| Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. | Journal of gastroenterology 20100801 |
| Sorafenib: a clinical and pharmacologic review. | Expert opinion on pharmacotherapy 20100801 |
| Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. | International journal of oncology 20100801 |
| Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. | Toxicologic pathology 20100801 |
| The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | Bioorganic & medicinal chemistry 20100801 |
| Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. | Cancer research 20100801 |
| [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801 |
| Tumor-stromal cell interactions and opportunities for therapeutic intervention. | Current opinion in pharmacology 20100801 |
| BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. | Molecular cancer research : MCR 20100801 |
| Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. | British journal of pharmacology 20100801 |
| Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. | Molecular cancer therapeutics 20100801 |
| Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801 |
| Novel therapies for hypereosinophilic syndromes. | The Netherlands journal of medicine 20100801 |
| [Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100801 |
| Sorafenib in hepatocellular carcinoma. | British journal of hospital medicine (London, England : 2005) 20100801 |
| [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100801 |
| Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. | World journal of gastroenterology 20100728 |
| Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100715 |
| Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. | Transplantation 20100715 |
| Sorafenib exerts anti-glioma activity in vitro and in vivo. | Neuroscience letters 20100712 |
| Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710 |
| Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. | Journal of hepato-biliary-pancreatic sciences 20100701 |
| Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. | Journal of cellular physiology 20100701 |
| Antiangiogenesis agents in colorectal cancer. | Current opinion in oncology 20100701 |
| Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. | Journal of hepatology 20100701 |
| New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. | Journal of hepatology 20100701 |
| The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. | Asian journal of andrology 20100701 |
| Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. | International journal of oncology 20100701 |
| The present and the future landscape of treatment of advanced hepatocellular carcinoma. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20100701 |
| Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. | The oncologist 20100701 |
| Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100701 |
| Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. | Molecular cancer therapeutics 20100701 |
| Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100701 |
| Sorafenib: where do we go from here? | Hepatology (Baltimore, Md.) 20100701 |
| A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100701 |
| Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. | Oncology 20100701 |
| Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. | Oncology 20100701 |
| Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. | Oncology 20100701 |
| Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. | International journal of clinical practice 20100701 |
| Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100701 |
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620 |
| Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. | Cancer research 20100615 |
| [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. | Orvosi hetilap 20100606 |
| Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. | American journal of clinical oncology 20100601 |
| Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. | Cancer investigation 20100601 |
| Hepatocellular carcinoma: sorafenib before liver transplantation? | Hepatology (Baltimore, Md.) 20100601 |
| Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. | Japanese journal of clinical oncology 20100601 |
| Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. | Growth factors (Chur, Switzerland) 20100601 |
| Update on systemic therapies of metastatic renal cell carcinoma. | World journal of urology 20100601 |
| Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting. | Annals of oncology : official journal of the European Society for Medical Oncology 20100601 |
| Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. | Current cancer drug targets 20100601 |
| Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. | The Journal of clinical endocrinology and metabolism 20100601 |
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100601 |
| Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. | Journal of gastrointestinal cancer 20100601 |
| Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. | International journal of oncology 20100601 |
| Treatment of metastatic renal cell carcinoma. | Nature reviews. Urology 20100601 |
| [Antiangionic drugs in soft tissue sarcoma]. | Bulletin du cancer 20100601 |
| [Focus on GIST management]. | Bulletin du cancer 20100601 |
| Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. | AJR. American journal of roentgenology 20100601 |
| A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. | Nature medicine 20100601 |
| Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. | The Journal of clinical endocrinology and metabolism 20100601 |
| [Anti-angiogenic drugs]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| [Current therapy for hepatocellular carcinoma]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. | Expert review of anticancer therapy 20100601 |
| [Effect of sorafenib combined with daunorubicin on K562 cell line]. | Zhongguo shi yan xue ye xue za zhi 20100601 |
| Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. | Journal of chemotherapy (Florence, Italy) 20100601 |
| Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. | HPB : the official journal of the International Hepato Pancreato Biliary Association 20100601 |
| Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. | HPB : the official journal of the International Hepato Pancreato Biliary Association 20100601 |
| Sorafenib and thyrotoxicosis. | Journal of endocrinological investigation 20100601 |
| Annular leukocytoclastic vasculitis associated with sorafenib administration. | Journal of drugs in dermatology : JDD 20100601 |
| Sorafenib-associated psoriasiform skin changes. | Cutis 20100601 |
| Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. | Analytical and quantitative cytology and histology 20100601 |
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100510 |
| [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. | Medicina clinica 20100508 |
| Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics. | Journal of proteome research 20100507 |
| Sorafenib-induced acute pancreatitis. | JOP : Journal of the pancreas 20100505 |
| Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. | Biochemistry 20100504 |
| Incidence of brain metastases in renal cell carcinoma treated with sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20100501 |
| The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. | Urology 20100501 |
| Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. | Cancer chemotherapy and pharmacology 20100501 |
| The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. | Journal of hepatology 20100501 |
| Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. | Journal of hepatology 20100501 |
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100501 |
| Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. | Expert opinion on investigational drugs 20100501 |
| Novel inhibitors in development for hepatocellular carcinoma. | Expert opinion on investigational drugs 20100501 |
| Systemic treatment of hepatocellular carcinoma: dawn of a new era? | Annals of surgical oncology 20100501 |
| Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501 |
| Drug therapy: sorafenib. | Hepatology (Baltimore, Md.) 20100501 |
| Editorial comment. | Urology 20100501 |
| Editorial comment. | Urology 20100501 |
| Clinical overview of sorafenib in breast cancer. | Future oncology (London, England) 20100501 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20100501 |
| Sorafenib for the treatment of advanced hepatocellular carcinoma. | Health technology assessment (Winchester, England) 20100501 |
| Non-pigmenting fixed drug eruption induced by sorafenib. | Acta dermato-venereologica 20100501 |
| Present state of target therapy for disseminated renal cell carcinoma. | Immunotherapy 20100501 |
| Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. | International journal of palliative nursing 20100501 |
| Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation. | Journal of the Chinese Medical Association : JCMA 20100501 |
| Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. | British journal of cancer 20100413 |
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. | Investigational new drugs 20100401 |
| The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. | International journal of cancer 20100401 |
| Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. | European journal of gastroenterology & hepatology 20100401 |
| Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. | Hepatology (Baltimore, Md.) 20100401 |
| Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. | Scandinavian journal of gastroenterology 20100401 |
| A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. | Gynecologic oncology 20100401 |
| Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). | The Lancet. Oncology 20100401 |
| Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. | The Lancet. Oncology 20100401 |
| Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. | The Lancet. Oncology 20100401 |
| Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. | Molecular cancer therapeutics 20100401 |
| Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. | Journal of chemotherapy (Florence, Italy) 20100401 |
| [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100401 |
| Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100320 |
| Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. | International journal of cancer 20100315 |
| Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. | Journal of cancer research and clinical oncology 20100301 |
| Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. | Cardiovascular toxicology 20100301 |
| [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. | Aktuelle Urologie 20100301 |
| Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. | Gastroenterology 20100301 |
| A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. | Clinical pharmacology and therapeutics 20100301 |
| Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. | Anti-cancer drugs 20100301 |
| Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. | The British journal of dermatology 20100301 |
| Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? | Current opinion in hematology 20100301 |
| The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. | European journal of cancer (Oxford, England : 1990) 20100301 |
| Toxicity of sorafenib: clinical and molecular aspects. | Expert opinion on drug safety 20100301 |
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. | Cancer 20100301 |
| Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. | Leukemia research 20100301 |
| Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. | Bioorganic & medicinal chemistry letters 20100301 |
| Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100301 |
| [Use of sorafenib in patients with hepatocellular or renal carcinoma]. | Gastroenterologie clinique et biologique 20100301 |
| Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. | Molecular cancer therapeutics 20100301 |
| Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. | Molecular cancer therapeutics 20100301 |
| Raf inhibitors as therapeutic agents against neurodegenerative diseases. | CNS & neurological disorders drug targets 20100301 |
| Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. | Neoplasia (New York, N.Y.) 20100301 |
| Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. | Targeted oncology 20100301 |
| [Chemotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100301 |
| The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. | Journal of gastroenterology and hepatology 20100301 |
| Molecular therapy of pancreatic cancer. | Minerva endocrinologica 20100301 |
| Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. | International journal of urology : official journal of the Japanese Urological Association 20100301 |
| Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. | Oncogene 20100225 |
| Identification of bona fide esophageal adenocarcinoma cell lines. | Journal of the National Cancer Institute 20100224 |
| Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. | Journal of the National Cancer Institute 20100224 |
| Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220 |
| FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Blood 20100218 |
| Review article: the management of hepatocellular carcinoma. | Alimentary pharmacology & therapeutics 20100215 |
| Sorafenib-associated remission of psoriasis in hypernephroma: case report. | Dermatology online journal 20100215 |
| Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. | British journal of cancer 20100202 |
| Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. | Cancer letters 20100201 |
| The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. | Research in veterinary science 20100201 |
| Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. | Annals of surgical oncology 20100201 |
| Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event. | Lung cancer (Amsterdam, Netherlands) 20100201 |
| VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. | Anti-cancer drugs 20100201 |
| Sorafenib - a small molecule with big promise? | Leukemia & lymphoma 20100201 |
| Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34. | The Journal of urology 20100201 |
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. | Molecular cancer therapeutics 20100201 |
| Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100201 |
| Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100201 |
| A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. | Leukemia & lymphoma 20100201 |
| Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? | The oncologist 20100201 |
| Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. | The oncologist 20100201 |
| Risk of bleeding not increased by sorafenib or sunitinib. | The Lancet. Oncology 20100201 |
| Current strategy for staging and treatment: the BCLC update and future prospects. | Seminars in liver disease 20100201 |
| Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. | Journal of drugs in dermatology : JDD 20100201 |
| Prognostic factors in patients treated with VEGF-targeted therapies. | Clinical advances in hematology & oncology : H&O 20100201 |
| [Treatment of locally advanced renal tumors]. | Actas urologicas espanolas 20100201 |
| Hepatocellular carcinoma--what's new? | Journal of visceral surgery 20100201 |
| CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. | British journal of cancer 20100119 |
| Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? | Clinical cancer research : an official journal of the American Association for Cancer Research 20100115 |
| Sorafenib-induced bilateral osteonecrosis of femoral heads. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100110 |
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. | British journal of cancer 20100105 |
| Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. | Urologic oncology 20100101 |
| Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. | Urologic oncology 20100101 |
| Sorafenib induces partial response in metastatic medullary thyroid carcinoma. | Acta oncologica (Stockholm, Sweden) 20100101 |
| Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. | Pediatric blood & cancer 20100101 |
| Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma. | Haemophilia : the official journal of the World Federation of Hemophilia 20100101 |
| Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101 |
| Acute aortic dissection during sorafenib-containing therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. | Cancer science 20100101 |
| Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. | Cancer 20100101 |
| Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. | Hepatology (Baltimore, Md.) 20100101 |
| Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| Where does the combination of sorafenib and interferon in renal cell carcinoma stand? | Cancer 20100101 |
| Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma. | Bioorganic & medicinal chemistry letters 20100101 |
| About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? | Annals of oncology : official journal of the European Society for Medical Oncology 20100101 |
| AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). | Journal of hepatology 20100101 |
| Evidence-based urology in practice: when to believe a subgroup analysis? | BJU international 20100101 |
| Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. | Journal of hepatology 20100101 |
| Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. | Urologic oncology 20100101 |
| Platelet count less than SHARP: what does a case series reveal? | Expert opinion on drug safety 20100101 |
| Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20100101 |
| Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. | AJR. American journal of roentgenology 20100101 |
| Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. | AJR. American journal of roentgenology 20100101 |
| Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. | Pharmacotherapy 20100101 |
| Compounds in clinical Phase III and beyond. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. | Hepatology (Baltimore, Md.) 20100101 |
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. | The oncologist 20100101 |
| Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. | Molecular cancer therapeutics 20100101 |
| Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. | Annual review of medicine 20100101 |
| Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101 |
| Sorafenib. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Managing adverse events associated with sorafenib in renal cell carcinoma. | British journal of nursing (Mark Allen Publishing) 20100101 |
| Progress in the management of advanced renal cell carcinoma (RCC). | Aktuelle Urologie 20100101 |
| A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma. | The Netherlands journal of medicine 20100101 |
| The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. | Molecular cancer 20100101 |
| [Renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100101 |
| Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. | Radiation oncology (London, England) 20100101 |
| Choroidal metastasis of renal cell carcinoma: a case report. | Japanese journal of ophthalmology 20100101 |
| [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]. | Onkologie 20100101 |
| Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. | Advances in experimental medicine and biology 20100101 |
| Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. | Gastroenterologie clinique et biologique 20100101 |
| [Treatment of advanced hepatocellular carcinoma]. | Gastroenterologia y hepatologia 20100101 |
| New therapeutic strategies for renal cell carcinoma. | Urologic nursing 20100101 |
| [Targeted therapies in hepatocellular carcinoma]. | Presse medicale (Paris, France : 1983) 20100101 |
| Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword. | Current problems in cancer 20100101 |
| Current problems with systemic treatment of advanced hepatocellular cancer. | Current problems in cancer 20100101 |
| [Renal cell carcinoma management and therapies in 2010]. | Bulletin du cancer 20100101 |
| [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. | Bulletin du cancer 20100101 |
| [Targeted therapies: sequential and combined treatments]. | Bulletin du cancer 20100101 |
| [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. | Bulletin du cancer 20100101 |
| [Advanced renal carcinomas with special situations. How to treat them?]. | Bulletin du cancer 20100101 |
| A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. | Oncology 20100101 |
| [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. | Therapie 20100101 |
| Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. | International journal of clinical and experimental pathology 20100101 |
| Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity. | Onkologie 20100101 |
| A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. | Internal medicine (Tokyo, Japan) 20100101 |
| Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. | Journal of experimental & clinical cancer research : CR 20100101 |
| Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. | Clinical drug investigation 20100101 |
| Targeted treatment for metastatic renal cell carcinoma and immune regulation. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101 |
| Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. | Genome biology 20100101 |
| Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. | European journal of medical research 20100101 |
| Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. | Hepato-gastroenterology 20100101 |
| Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. | Chemotherapy 20100101 |
| Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? | Dermatology (Basel, Switzerland) 20100101 |
| Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20100101 |
| Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. | Oncology 20100101 |
| [Nexavar clinical registry]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. | Acta haematologica 20100101 |
| A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. | International journal of immunopathology and pharmacology 20100101 |
| The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. | BMC cancer 20100101 |
| Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. | European journal of dermatology : EJD 20100101 |
| Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. | Urologia internationalis 20100101 |
| Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. | Hepato-gastroenterology 20100101 |
| Treatment with sorafenib in advanced thyroid cancer - a case report. | Endokrynologia Polska 20100101 |
| [Hand-foot syndrome after administration of tyrosinkinase inhibitors]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Antiangiogenic therapy for breast cancer. | Breast cancer research : BCR 20100101 |
| Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. | Oncology 20100101 |
| Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. | Oncology 20100101 |
| Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? | The oncologist 20100101 |
| RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development. | PloS one 20100101 |
| A phase II trial of sorafenib in metastatic melanoma with tissue correlates. | PloS one 20100101 |
| Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? | Tumori 20100101 |
| [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? | Pediatric blood & cancer 20091215 |
| The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. | Journal of immunology (Baltimore, Md. : 1950) 20091215 |
| UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. | Cancer chemotherapy and pharmacology 20091201 |
| Rectal fistulae resulting from treatment with sorafenib and bevacizumab. | Gastrointestinal endoscopy 20091201 |
| Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. | Cancer treatment reviews 20091201 |
| New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. | Gut 20091201 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors. | Cancer treatment reviews 20091201 |
| Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. | European journal of endocrinology 20091201 |
| Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. | Hepatology (Baltimore, Md.) 20091201 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201 |
| Sorafenib-induced hepatic encephalopathy. | The Annals of pharmacotherapy 20091201 |
| Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? | Targeted oncology 20091201 |
| Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201 |
| Tyrosine kinase inhibitors and the thyroid. | Best practice & research. Clinical endocrinology & metabolism 20091201 |
| Sorafenib-induced acute myocardial infarction due to coronary artery spasm. | Journal of cardiology 20091201 |
| Metastatic renal cell carcinoma: current standards of care. | Clinical journal of oncology nursing 20091201 |
| Management of vascular endothelial growth factor and multikinase inhibitor side effects. | Clinical journal of oncology nursing 20091201 |
| Health policy: The UK 'postcode lottery' in renal cell carcinoma. | Nature reviews. Urology 20091201 |
| [Sorafenib-induced multiple eruptive keratoacanthomas]. | Annales de dermatologie et de venereologie 20091201 |
| Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20091201 |
| [Targeting KRAS pathway in NSCLC therapy]. | Bulletin du cancer 20091201 |
| Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. | Cancer biology & therapy 20091201 |
| Tyrosine kinase inhibitor-induced macrocytosis. | Anticancer research 20091201 |
| Hepatocellular carcinoma: the search for innovative adjuvant therapies. | Oncology (Williston Park, N.Y.) 20091201 |
| Targeted molecular therapies in thyroid carcinoma. | Arquivos brasileiros de endocrinologia e metabologia 20091201 |
| Highlights from the Eigth International Kidney Cancer Symposium. | Clinical advances in hematology & oncology : H&O 20091201 |
| Baying for a flexible drug price. | Lancet (London, England) 20091128 |
| NICE rules that drug used in advanced liver cancer is not cost effective for the NHS. | BMJ (Clinical research ed.) 20091123 |
| Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. | British journal of cancer 20091117 |
| Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091115 |
| MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. | The Journal of biological chemistry 20091113 |
| C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). | Molecular cell 20091113 |
| Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. | The British journal of dermatology 20091101 |
| Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20091101 |
| Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. | Journal of hepatology 20091101 |
| Therapy for metastatic RCC--questions remain. | Nature reviews. Urology 20091101 |
| Everolimus: in advanced renal cell carcinoma. | Drugs 20091022 |
| Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). | Cancer 20091015 |
| A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001 |
| Erythema multiforme induced by sorafenib. | Clinical and experimental dermatology 20091001 |
| Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. | International journal of cancer 20091001 |
| AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). | Blood 20091001 |
| Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. | Journal of hepatology 20091001 |
| Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20091001 |
| Hepatocellular carcinoma: The beginning of a long journey. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20091001 |
| Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. | American journal of hematology 20091001 |
| An overview of small-molecule inhibitors of VEGFR signaling. | Nature reviews. Clinical oncology 20091001 |
| Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | The Lancet. Oncology 20091001 |
| Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. | AJR. American journal of roentgenology 20091001 |
| Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. | Cancer biology & therapy 20091001 |
| Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| [Palmoplantar cutaneous reaction to sorafenib]. | Actas dermo-sifiliograficas 20091001 |
| Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf. | Journal of pharmacological sciences 20091001 |
| Rapid development of hypertension by sorafenib: toxicity or target? | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. | Expert review of anticancer therapy 20091001 |
| Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient. | International journal of clinical oncology 20091001 |
| Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. | Journal of the American Chemical Society 20090923 |
| Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. | World journal of gastroenterology 20090921 |
| Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. | Cancer 20090915 |
| C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| Long-term response in primary renal cancer to sequential antiangiogenic therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. | Journal of neurosurgery 20090901 |
| Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. | Current opinion in supportive and palliative care 20090901 |
| Targeted therapies in the treatment of advanced/metastatic NSCLC. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Surgical resection of renal cell carcinoma after targeted therapy. | The Journal of urology 20090901 |
| Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. | Cancer biology & therapy 20090901 |
| A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. | Laboratory investigation; a journal of technical methods and pathology 20090901 |
| The histologic spectrum of epithelial neoplasms induced by sorafenib. | Journal of the American Academy of Dermatology 20090901 |
| Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. | Nature reviews. Clinical oncology 20090901 |
| AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. | Molecular cancer therapeutics 20090901 |
| Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. | Neoplasia (New York, N.Y.) 20090901 |
| Molecular targeting for treatment of advanced hepatocellular carcinoma. | The Korean journal of hepatology 20090901 |
| [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. | Cancer research 20090815 |
| Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810 |
| [Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090810 |
| Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. | Journal of the European Academy of Dermatology and Venereology : JEADV 20090801 |
| Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. | Journal of cellular and molecular medicine 20090801 |
| Hyperkeratosis of nipple skin during sorafenib treatment. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20090801 |
| Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. | Clinical and experimental nephrology 20090801 |
| Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. | Molecular pharmacology 20090801 |
| BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. | Molecular pharmacology 20090801 |
| Adverse effects of anticancer agents that target the VEGF pathway. | Nature reviews. Clinical oncology 20090801 |
| Array of cutaneous adverse effects associated with sorafenib. | Journal of the American Academy of Dermatology 20090801 |
| Tumor endothelial cells join the resistance. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090801 |
| Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090801 |
| Diagnosis and management of leptomeningeal disease. | Clinical journal of oncology nursing 20090801 |
| Sorafenib and sunitinib. | The oncologist 20090801 |
| Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. | Future oncology (London, England) 20090801 |
| [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402]. | Ai zheng = Aizheng = Chinese journal of cancer 20090801 |
| Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. | Molecular cancer therapeutics 20090801 |
| Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. | Clinical genitourinary cancer 20090801 |
| Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. | Anti-cancer drugs 20090801 |
| Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715 |
| Targeting renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090710 |
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090710 |
| Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib. | The British journal of ophthalmology 20090701 |
| Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. | Journal of cellular physiology 20090701 |
| Sorafenib tosylate in advanced kidney cancer: past, present and future. | Anti-cancer drugs 20090701 |
| Sequential sorafenib and sunitinib for renal cell carcinoma. | The Journal of urology 20090701 |
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701 |
| VEGF inhibition and metastasis: possible implications for antiangiogenic therapy. | Cancer biology & therapy 20090701 |
| Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. | Nuclear medicine communications 20090701 |
| Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. | Nature reviews. Urology 20090701 |
| Multiple Histology Phase II Trials. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090701 |
| Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. | Deutsche medizinische Wochenschrift (1946) 20090701 |
| Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. | The American journal of gastroenterology 20090701 |
| Current management of hepatocellular carcinoma. | The Medical clinics of North America 20090701 |
| Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. | Blood 20090625 |
| NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. | Cancer letters 20090618 |
| The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. | Biochemistry 20090616 |
| How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. | Journal of the National Cancer Institute 20090616 |
| Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. | Cancer immunology, immunotherapy : CII 20090601 |
| Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. | European urology 20090601 |
| Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. | European urology 20090601 |
| Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. | BJU international 20090601 |
| A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. | Allergy 20090601 |
| Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. | Minerva gastroenterologica e dietologica 20090601 |
| [Toxicity of radiation therapy and antiangiogenics combination: a case report]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20090601 |
| A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. | Journal of hepatology 20090601 |
| Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090601 |
| BRAF signaling and targeted therapies in melanoma. | Hematology/oncology clinics of North America 20090601 |
| Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? | Radiology 20090601 |
| Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. | Expert review of anticancer therapy 20090601 |
| The role of antiangiogenesis therapy: bevacizumab and beyond. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090601 |
| Localized dyskeratotic plaque with milia associated with sorafenib. | Journal of drugs in dermatology : JDD 20090601 |
| [Sorafenib(Nexavar)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090601 |
| [Current advances in molecular targeted therapy of primary hepatocellular carcinoma]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090601 |
| [Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report]. | Hinyokika kiyo. Acta urologica Japonica 20090601 |
| VEGF inhibitors and prostate cancer therapy. | Current molecular pharmacology 20090601 |
| [Expert consensus on standardization of the management of primary liver cancer]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090601 |
| Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. | Cancer letters 20090518 |
| Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. | Cancer 20090515 |
| Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20090501 |
| FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. | Leukemia 20090501 |
| Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. | Journal of pharmaceutical and biomedical analysis 20090501 |
| Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. | International journal of urology : official journal of the Japanese Urological Association 20090501 |
| [Targeted therapies and their indications in solid neoplasias]. | La Revue de medecine interne 20090501 |
| Targeting angiogenesis in bladder cancer. | Current oncology reports 20090501 |
| Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. | Japanese journal of clinical oncology 20090501 |
| Targeted therapies in metastatic renal cancer in 2009. | BJU international 20090501 |
| Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. | British journal of pharmacology 20090501 |
| Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. | Cancer research 20090501 |
| Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. | Current cardiology reports 20090501 |
| Pathogenesis of hepatocellular carcinoma and molecular therapies. | Current opinion in gastroenterology 20090501 |
| Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| Prognostic markers and new, innovative treatments in renal cell carcinoma. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20090501 |
| Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? | Thyroid : official journal of the American Thyroid Association 20090501 |
| [Sorafenib reverses multidrug resistance of hepatoma cells in vitro]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090501 |
| Angiogenesis regulated by VEGF and its receptors and its clinical application. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20090501 |
| Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. | Journal of the National Cancer Institute 20090415 |
| Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410 |
| Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. | British journal of cancer 20090407 |
| [The treatment of hepatocellular carcinoma. New developments]. | Nederlands tijdschrift voor geneeskunde 20090404 |
| Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. | Journal of cancer research and clinical oncology 20090401 |
| Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. | European urology 20090401 |
| Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. | Hepatology (Baltimore, Md.) 20090401 |
| Phase II trial of sorafenib in metastatic thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090401 |
| Efficient exploration of large combinatorial chemistry spaces by monomer-based similarity searching. | Journal of chemical information and modeling 20090401 |
| FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. | Cancer research 20090401 |
| [Hepatocellular carcinoma management in the era of sorafenib]. | Gastroenterologie clinique et biologique 20090401 |
| Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. | Pharmacotherapy 20090401 |
| Antiangiogenic therapy: not just for cancer anymore? | Hepatology (Baltimore, Md.) 20090401 |
| Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. | Nature reviews. Clinical oncology 20090401 |
| PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? | Expert opinion on therapeutic targets 20090401 |
| [Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20090401 |
| The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. | Thyroid : official journal of the American Thyroid Association 20090401 |
| Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). | Biochimica et biophysica acta 20090401 |
| Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. | Targeted oncology 20090401 |
| Selection of patients with hepatocellular carcinoma for sorafenib. | Journal of the National Comprehensive Cancer Network : JNCCN 20090401 |
| Renal toxicity of targeted therapies. | Targeted oncology 20090401 |
| Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310 |
| Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. | European journal of cancer (Oxford, England : 1990) 20090301 |
| Multimodal approaches to the treatment of hepatocellular carcinoma. | Nature clinical practice. Gastroenterology & hepatology 20090301 |
| Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma. | The Journal of investigative dermatology 20090301 |
| Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. | Cancer chemotherapy and pharmacology 20090301 |
| Recent advances in the systemic treatment of metastatic papillary renal cancer. | Expert review of anticancer therapy 20090301 |
| Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. | Molecular cancer therapeutics 20090301 |
| Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. | Molecular cancer research : MCR 20090301 |
| Systemic treatment in hepatocellular carcinoma; 'A small step for man...'. | The Netherlands journal of medicine 20090301 |
| Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. | Clinical lung cancer 20090301 |
| [Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)]. | Revue medicale de Liege 20090301 |
| [Diagnosis and treatment of hepatocellular carcinoma]. | Medicina clinica 20090227 |
| Major achievements in hepatocellular carcinoma. | Lancet (London, England) 20090221 |
| Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090220 |
| Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090201 |
| Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. | Leukemia research 20090201 |
| Dermatologic symptoms associated with the multikinase inhibitor sorafenib. | Journal of the American Academy of Dermatology 20090201 |
| Treating hepatocellular carcinoma without liver transplantation. | Current gastroenterology reports 20090201 |
| Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090201 |
| MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. | Molecular cancer therapeutics 20090201 |
| Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. | Onkologie 20090201 |
| Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. | Onkologie 20090201 |
| Sorafenib is active on lung metastases from synovial sarcoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20090201 |
| [Hand-foot syndrome and sorafenib]. | Bulletin du cancer 20090201 |
| Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. | Cancer 20090115 |
| Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115 |
| Molecular therapy for the treatment of hepatocellular carcinoma. | British journal of cancer 20090113 |
| Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110 |
| CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. | Oncogene 20090108 |
| Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. | Journal of cancer research and clinical oncology 20090101 |
| Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. | Journal of neuro-oncology 20090101 |
| Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. | Medical oncology (Northwood, London, England) 20090101 |
| Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. | Cancer science 20090101 |
| Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101 |
| Quo vadis with targeted drugs in the 21st century? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090101 |
| Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. | Cancer 20090101 |
| Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. | Clinical drug investigation 20090101 |
| Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. | Cancer control : journal of the Moffitt Cancer Center 20090101 |
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | The Lancet. Oncology 20090101 |
| Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. | The American journal of gastroenterology 20090101 |
| Sorafenib for liver cancer: the horizon broadens. | The Lancet. Oncology 20090101 |
| Management of advanced hepatocellular carcinoma in the era of targeted therapy. | Liver international : official journal of the International Association for the Study of the Liver 20090101 |
| Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. | Molecular cancer therapeutics 20090101 |
| Sorafenib for the treatment of unresectable hepatocellular carcinoma. | The oncologist 20090101 |
| Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning? | The oncologist 20090101 |
| Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. | The oncologist 20090101 |
| Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. | The oncologist 20090101 |
| [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]. | Zeitschrift fur Gastroenterologie 20090101 |
| Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. | BMC cancer 20090101 |
| [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. | Aktuelle Urologie 20090101 |
| [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. | Aktuelle Urologie 20090101 |
| Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. | International journal of clinical pharmacology and therapeutics 20090101 |
| New drugs for the treatment of hepatocellular carcinoma. | Liver international : official journal of the International Association for the Study of the Liver 20090101 |
| Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm. | Clinical genitourinary cancer 20090101 |
| Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. | Clinical genitourinary cancer 20090101 |
| Sorafenib: a review of its use in advanced hepatocellular carcinoma. | Drugs 20090101 |
| Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20090101 |
| Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. | Journal of clinical gastroenterology 20090101 |
| Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. | Oncology 20090101 |
| Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. | BMC pharmacology 20090101 |
| Selecting promising treatments in randomized Phase II cancer trials with an active control. | Journal of biopharmaceutical statistics 20090101 |
| [Prospect of hepatocellular carcinoma in 2008]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090101 |
| Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. | The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20090101 |
| The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. | Acta oncologica (Stockholm, Sweden) 20090101 |
| A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. | Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg 20090101 |
| Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. | Cutaneous and ocular toxicology 20090101 |
| [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090101 |
| Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. | BMC cancer 20090101 |
| Target therapy for hepatocellular carcinoma: is sorafenib for everybody? | Journal of clinical gastroenterology 20090101 |
| Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. | BMC cancer 20090101 |
| A case of complete clinical response with sorafenib in a patient with thyroid gland metastases from renal cell carcinoma 17 years from diagnosis. | Tumori 20090101 |
| Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. | BMC medicine 20090101 |
| Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? | BMC medicine 20090101 |
| Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma. | Pediatric dermatology 20090101 |
| [Dermatologic toxicity to sorafenib]. | Actas dermo-sifiliograficas 20090101 |
| [Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| New therapeutic approaches in the management of metastatic renal cell carcinoma. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101 |
| Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. | Tumori 20090101 |
| Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. | BMC cancer 20090101 |
| Successful treatment of a brain-metastasized renal cell carcinoma. | German medical science : GMS e-journal 20090101 |
| Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. | Oncology 20090101 |
| Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Generalized convulsions due to sorafenib-induced hypocalcemia. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20090101 |
| New pharmacological developments in the treatment of hepatocellular cancer. | Drugs 20090101 |
| Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. | Molecular cancer 20090101 |
| Sorafenib in hepatocellular carcinoma: separating the hype from the hope. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081220 |
| Targeting metastatic melanoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081215 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081210 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20081204 |
| Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. | Digestive diseases and sciences 20081201 |
| Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. | European urology 20081201 |
| Exploring the role of novel agents in the treatment of renal cell carcinoma. | Cancer treatment reviews 20081201 |
| Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. | Alimentary pharmacology & therapeutics 20081201 |
| Vascular complications of selected cancer therapies. | Nature clinical practice. Cardiovascular medicine 20081201 |
| Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. | Nature clinical practice. Oncology 20081201 |
| [Vascular and renal effects of anti-angiogenic therapy]. | Nephrologie & therapeutique 20081201 |
| Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. | Current medical research and opinion 20081201 |
| Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. | Cancer research 20081201 |
| Potential role of sorafenib in the treatment of acute myeloid leukemia. | Leukemia & lymphoma 20081201 |
| Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20081201 |
| Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines. | Biomedical research (Tokyo, Japan) 20081201 |
| Evolution of systemic therapy of advanced hepatocellular carcinoma. | World journal of gastroenterology 20081114 |
| Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. | Circulation 20081111 |
| Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20081101 |
| Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. | Toxicological sciences : an official journal of the Society of Toxicology 20081101 |
| Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20081101 |
| [Molecular basis of targeted therapy in metastatic renal cancer]. | Der Pathologe 20081101 |
| Systemic therapy of hepatocellular carcinoma: are we making progress? | Advances in therapy 20081101 |
| Systemic therapy for metastatic renal cell carcinoma. | The Urologic clinics of North America 20081101 |
| Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. | Molecular cancer therapeutics 20081101 |
| Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. | Journal of the National Cancer Institute 20081015 |
| Phase II trial of sorafenib in advanced thyroid cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010 |
| [Targeted therapy for metastatic bladder cancer]. | Der Urologe. Ausg. A 20081001 |
| [Value of targeted therapies for renal cell cancer]. | Der Urologe. Ausg. A 20081001 |
| [Targeted therapy - point blank or single shot]. | Der Urologe. Ausg. A 20081001 |
| Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. | Urology 20081001 |
| About sorafenib in castration-resistant prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20081001 |
| Searching for the Achilles' heel of melanoma cells: new treatment modalities. | Pigment cell & melanoma research 20081001 |
| Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. | Cancer biology & therapy 20081001 |
| Novel drugs for renal cell carcinoma. | Expert opinion on investigational drugs 20081001 |
| Molecular targeted therapies in hepatocellular carcinoma. | Hepatology (Baltimore, Md.) 20081001 |
| Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001 |
| [Systemic therapy of metastasizing renal cell carcinoma]. | Der Urologe. Ausg. A 20081001 |
| Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. | European journal of cancer (Oxford, England : 1990) 20081001 |
| Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. | The oncologist 20081001 |
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. | Molecular cancer therapeutics 20081001 |
| [Eruptive nevi associated with sorafenib treatment]. | Annales de dermatologie et de venereologie 20081001 |
| Drug essentials. Small molecule multitargeted TKI therapy. | Oncology (Williston Park, N.Y.) 20081001 |
| Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. | Cancer 20080915 |
| Major treatment improvements encourage kidney cancer researchers to seek further gains. | Journal of the National Cancer Institute 20080903 |
| Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. | BJU international 20080901 |
| Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20080901 |
| Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. | Cancer science 20080901 |
| von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. | The Journal of urology 20080901 |
| A Kaposi's sarcoma complete clinical response after sorafenib administration. | Annals of oncology : official journal of the European Society for Medical Oncology 20080901 |
| Targeted therapy in renal cell carcinoma. | Current opinion in urology 20080901 |
| Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 |
| Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. | The oncologist 20080901 |
| [Renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080901 |
| [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. | Bulletin du cancer 20080901 |
| [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. | Magyar onkologia 20080901 |
| Cutaneous drug eruptions induced by sorafenib: a case series. | Journal of drugs in dermatology : JDD 20080901 |
| Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820 |
| Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080815 |
| Watchdog set to reject four drugs for kidney cancer on the NHS. | BMJ (Clinical research ed.) 20080814 |
| Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. | The Journal of investigative dermatology 20080801 |
| Challenges and pitfalls of combining targeted agents in phase I studies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801 |
| Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801 |
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080801 |
| Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080801 |
| Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. | Cancer research 20080801 |
| Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. | The oncologist 20080801 |
| Effectively targeting BRAF in melanoma: a formidable challenge. | Pigment cell & melanoma research 20080801 |
| Contemporary management of hepatocellular carcinoma. | Clinical medicine (London, England) 20080801 |
| Sorafenib-induced liver failure. | The American journal of gastroenterology 20080801 |
| [Molecular targeted therapy for renal cell carcinoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20080801 |
| [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080801 |
| Medical therapies to extend survival in hepatocellular carcinoma. | Clinical advances in hematology & oncology : H&O 20080801 |
| Sorafenib in advanced hepatocellular carcinoma. | The New England journal of medicine 20080724 |
| Sorafenib in liver cancer--just the beginning. | The New England journal of medicine 20080724 |
| [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008]. | Orvosi hetilap 20080713 |
| Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710 |
| Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. | Cancer science 20080701 |
| Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. | The Journal of urology 20080701 |
| Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? | Nature clinical practice. Oncology 20080701 |
| Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. | AJR. American journal of roentgenology 20080701 |
| Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. | Oncology nursing forum 20080701 |
| Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. | Onkologie 20080701 |
| [Regression of vena cava tumour thrombus in response to sorafenib]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701 |
| A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. | International journal of dermatology 20080701 |
| Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. | Archives of dermatology 20080701 |
| [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701 |
| Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. | Blood 20080615 |
| Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. | Acta ophthalmologica 20080601 |
| Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. | Leukemia 20080601 |
| Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. | Cancer biology & therapy 20080601 |
| Early clinical studies of novel therapies for thyroid cancers. | Endocrinology and metabolism clinics of North America 20080601 |
| Targeted therapy in advanced non-small-cell lung cancer. | Seminars in respiratory and critical care medicine 20080601 |
| Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Sorafenib in lung cancer: clinical developments and future directions. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601 |
| K-ras as a target for lung cancer therapy. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601 |
| [Oncology 2008]. | Deutsche medizinische Wochenschrift (1946) 20080601 |
| Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. | Archives of dermatology 20080601 |
| Sorafenib-induced eruptive melanocytic lesions. | Archives of dermatology 20080601 |
| Sorafenib-induced palmoplantar hyperkeratosis. | Journal of drugs in dermatology : JDD 20080601 |
| Reader seeks clarification on hand-foot skin reaction. | Clinical journal of oncology nursing 20080601 |
| 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. | The oncologist 20080601 |
| [Lung cancer]. | Medizinische Klinik (Munich, Germany : 1983) 20080515 |
| Bowel perforation after radiotherapy in a patient receiving sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510 |
| Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. | European urology 20080501 |
| Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;53:376-81. | European urology 20080501 |
| Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. | Hepatology (Baltimore, Md.) 20080501 |
| Renal cell carcinoma. | Current opinion in oncology 20080501 |
| Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. | Molecular cancer therapeutics 20080501 |
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080501 |
| Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. | Molecular cancer therapeutics 20080501 |
| Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. | Physiological genomics 20080422 |
| Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. | Cancer 20080415 |
| Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. | Cancer chemotherapy and pharmacology 20080401 |
| [Renal cell carcinoma and antiangiogenic therapies]. | Presse medicale (Paris, France : 1983) 20080401 |
| A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20080401 |
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Leukemia 20080401 |
| Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. | Cancer biology & therapy 20080401 |
| Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy. | Melanoma research 20080401 |
| Chemotherapeutic agents and the skin: An update. | Journal of the American Academy of Dermatology 20080401 |
| Mcl-1: a gateway to TRAIL sensitization. | Cancer research 20080401 |
| Sorafenib for metastatic renal cancer: the Princess Margaret experience. | American journal of clinical oncology 20080401 |
| Treatment options for metastatic renal cell carcinoma: a review. | The Canadian journal of urology 20080401 |
| Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Molecular cancer therapeutics 20080401 |
| [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080401 |
| Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer. | Journal of the National Cancer Institute 20080319 |
| Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. | The British journal of dermatology 20080301 |
| New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. | The oncologist 20080301 |
| [New drugs; sunitinib and sorafenib]. | Nederlands tijdschrift voor geneeskunde 20080223 |
| A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. | Journal of the National Cancer Institute 20080220 |
| [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. | Nederlands tijdschrift voor geneeskunde 20080216 |
| Examining heterogeneity in phase II trial designs may improve success in phase III. | Journal of the National Cancer Institute 20080206 |
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. | Journal of the National Cancer Institute 20080206 |
| High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. | European urology 20080201 |
| Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20080201 |
| New developments in multitargeted therapy for patients with solid tumours. | Cancer treatment reviews 20080201 |
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. | The Lancet. Oncology 20080201 |
| Quantifying hypertension in patients with cancer treated with sorafenib. | The Lancet. Oncology 20080201 |
| Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. | Mayo Clinic proceedings 20080201 |
| FDA approves sorafenib for patients with inoperable liver cancer. | Gastroenterology 20080201 |
| [Cutaneous side effects of sorafenib and sunitinib]. | Annales de dermatologie et de venereologie 20080201 |
| Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. | Journal of pharmaceutical and biomedical analysis 20080122 |
| Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. | Cancer 20080115 |
| Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080115 |
| GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. | The Journal of biological chemistry 20080111 |
| Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. | Cancer science 20080101 |
| Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. | The Journal of urology 20080101 |
| Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101 |
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080101 |
| Sorafenib: in hepatocellular carcinoma. | Drugs 20080101 |
| Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature. | Medical oncology (Northwood, London, England) 20080101 |
| Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. | Acta oncologica (Stockholm, Sweden) 20080101 |
| [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. | Bulletin du cancer 20080101 |
| [News in digestive oncology]. | Bulletin du cancer 20080101 |
| [Molecular targeted therapy for renal cell carcinoma]. | Hinyokika kiyo. Acta urologica Japonica 20080101 |
| From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Current medicinal chemistry 20080101 |
| The role of angiogenesis inhibitors in prostate cancer. | Cancer journal (Sudbury, Mass.) 20080101 |
| Novel advancements in the management of hepatocellular carcinoma in 2008. | Journal of hepatology 20080101 |
| Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. | Toxicologic pathology 20080101 |
| [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]. | Gastroenterologie clinique et biologique 20080101 |
| [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. | Annales de dermatologie et de venereologie 20080101 |
| Sorafenib, a systemic therapy for hepatocellular carcinoma. | Annals of hepatology 20080101 |
| [The role of angiogenesis in renal carcinoma]. | Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101 |
| Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. | Urologia internationalis 20080101 |
| Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453. | Urologia internationalis 20080101 |
| An update on the medical therapy of advanced metastatic renal cell carcinoma. | Scandinavian journal of urology and nephrology 20080101 |
| Promising newer molecular-targeted therapies in head and neck cancer. | Drugs 20080101 |
| [New therapeutic regimes in metastasic renal-cell carcinoma]. | Der Internist 20080101 |
| Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. | Oncology 20080101 |
| Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. | Oncology 20080101 |
| Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. | Journal of translational medicine 20080101 |
| Signaling inhibitors in metastatic renal cell carcinoma. | Cancer journal (Sudbury, Mass.) 20080101 |
| Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. | Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20080101 |
| Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. | Journal of hematology & oncology 20080101 |
| Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib. | Clinical drug investigation 20080101 |
| Severe cutaneous reaction to sorafenib: induction of tolerance. | Acta dermato-venereologica 20080101 |
| Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. | BMC cancer 20080101 |
| [New drugs; sunitinib and sorafenib]. | Nederlands tijdschrift voor geneeskunde 20071229 |
| A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. | British journal of cancer 20071203 |
| Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. | The oncologist 20071201 |
| Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. | Clinical and experimental medicine 20071201 |
| FLT3 kinase inhibitors in the management of acute myeloid leukemia. | Clinical lymphoma & myeloma 20071201 |
| Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. | BioEssays : news and reviews in molecular, cellular and developmental biology 20071101 |
| Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20071101 |
| Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. | Dermatology online journal 20071013 |
| Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. | The Journal of biological chemistry 20071012 |
| Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. | The Journal of biological chemistry 20071005 |
| Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. | Journal of the National Cancer Institute 20071003 |
| Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. | Experimental hematology 20071001 |
| Managing side effects of angiogenesis inhibitors in renal cell carcinoma. | Onkologie 20071001 |
| Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. | Cancer research 20071001 |
| The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. | Cancer research 20071001 |
| Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. | Japanese journal of clinical oncology 20071001 |
| Sorafenib: a promising new targeted therapy for renal cell carcinoma. | Clinical journal of oncology nursing 20071001 |
| Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. | The oncologist 20071001 |
| [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. | Bulletin du cancer 20071001 |
| Sorafenib TARGET trial results in Spanish patients. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20071001 |
| New therapies in renal cell carcinoma. | Current opinion in supportive and palliative care 20071001 |
| Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. | World journal of gastroenterology 20070907 |
| Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10. | European urology 20070901 |
| The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. | Molecular pharmacology 20070901 |
| [Application monitoring of the use of sorafenib in papillary renal cell carcinoma]. | Der Urologe. Ausg. A 20070901 |
| Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. | Current oncology reports 20070901 |
| Treatment options in renal cell carcinoma: past, present and future. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. | Onkologie 20070901 |
| Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. | Expert review of anticancer therapy 20070901 |
| Acute pancreatitis associated with sorafenib. | Southern medical journal 20070901 |
| Sunitinib, sorafenib and mTOR inhibitors in renal cancer. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901 |
| Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070820 |
| Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report. | European urology 20070801 |
| Interstitial nephritis in a patient taking sorafenib. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801 |
| The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. | Molecular and cellular biology 20070801 |
| Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | Cancer 20070801 |
| Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. | Radiology 20070801 |
| Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. | Pharmacotherapy 20070801 |
| Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801 |
| Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801 |
| American Society of Clinical Oncology--43rd annual meeting. Translating research into practice. | IDrugs : the investigational drugs journal 20070801 |
| [The hepatocellular carcinoma: alternative therapeutical strategies]. | Zentralblatt fur Chirurgie 20070801 |
| Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? | Oncology (Williston Park, N.Y.) 20070801 |
| Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. | JAMA 20070718 |
| Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070701 |
| Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. | Cancer cell 20070701 |
| Sorafenib [corrected] in kidney cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070701 |
| [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma]. | Aktuelle Urologie 20070701 |
| [Oral drugs inhibiting the VEGF pathway]. | Bulletin du cancer 20070701 |
| [Angiogenesis and renal cell carcinoma]. | Bulletin du cancer 20070701 |
| [Cutaneous side effects of antiangiogenic agents]. | Bulletin du cancer 20070701 |
| Targeting ELF in therapy of liver cancer. | Cancer biology & therapy 20070701 |
| Mechanisms of adverse effects of anti-VEGF therapy for cancer. | British journal of cancer 20070618 |
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Oncogene 20070607 |
| ASCO 2006 highlights: targeted therapy for renal cell carcinoma. | Cancer treatment reviews 20070601 |
| Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. | The British journal of dermatology 20070601 |
| Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070601 |
| Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. | American journal of clinical oncology 20070601 |
| Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. | Molecular cancer therapeutics 20070601 |
| Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. | Annals of oncology : official journal of the European Society for Medical Oncology 20070601 |
| Can sorafenib cause hypothyroidism? | Journal of chemotherapy (Florence, Italy) 20070601 |
| B-Raf kinase inhibitors for cancer treatment. | Current opinion in investigational drugs (London, England : 2000) 20070601 |
| ASCO 2007: plenary top 5. | Oncology (Williston Park, N.Y.) 20070601 |
| [Promising new treatment options for metastatic androgen-independent prostate cancer]. | Actas urologicas espanolas 20070601 |
| [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. | Praxis 20070502 |
| Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. | Biochemical pharmacology 20070501 |
| [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. | Der Urologe. Ausg. A 20070501 |
| Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. | BJU international 20070501 |
| Combination of target agents: challenges and opportunities. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070501 |
| Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. | Nature reviews. Cancer 20070501 |
| Angiogenesis in cancer: molecular mechanisms, clinical impact. | Langenbeck's archives of surgery 20070501 |
| Do the results of the new trials change the standard treatment of metastatic renal cell cancer? | Onkologie 20070501 |
| Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |
| Sorafenib: delivering a targeted drug to the right targets. | Expert review of anticancer therapy 20070501 |
| A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. | Clinical lung cancer 20070501 |
| Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. | Reviews on recent clinical trials 20070501 |
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. | Cancer chemotherapy and pharmacology 20070401 |
| [Clinical studies with sorafenib (Nexavar) in metastatic melanoma]. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20070401 |
| Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. | Cancer research 20070401 |
| Pulmonary blastoma with renal metastasis responds to sorafenib. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401 |
| Sorafenib-induced pancreatitis. | Mayo Clinic proceedings 20070401 |
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. | The oncologist 20070401 |
| Design of clinical trials of radiation combined with antiangiogenic therapy. | The oncologist 20070401 |
| The effect of recent drug approvals on translational research and drug development. | Clinical advances in hematology & oncology : H&O 20070401 |
| Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070315 |
| Antitumor activity of sorafenib in FLT3-driven leukemic cells. | Leukemia 20070301 |
| Sorafenib-induced erythema multiforme. | Journal of the American Academy of Dermatology 20070301 |
| Drug insight: VEGF as a therapeutic target for breast cancer. | Nature clinical practice. Oncology 20070301 |
| Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. | Southern medical journal 20070301 |
| Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. | Clinical genitourinary cancer 20070301 |
| Two new drugs for renal cell carcinoma. | The Medical letter on drugs and therapeutics 20070226 |
| Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070215 |
| Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. | Cancer chemotherapy and pharmacology 20070201 |
| A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070201 |
| New drugs 07, part I. | Nursing 20070201 |
| American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA. | IDrugs : the investigational drugs journal 20070201 |
| Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. | The oncologist 20070201 |
| [Clinical results of Nexavar for the treatment of kidney cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070201 |
| Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. | Current treatment options in oncology 20070201 |
| Hand-foot and stump syndrome to sorafenib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070120 |
| Sorafenib in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070115 |
| Sorafenib in advanced clear-cell renal-cell carcinoma. | The New England journal of medicine 20070111 |
| Renal-cell carcinoma--molecular pathways and therapies. | The New England journal of medicine 20070111 |
| Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. | European journal of cancer (Oxford, England : 1990) 20070101 |
| Keratoacanthomas associated with sorafenib therapy. | Journal of the American Academy of Dermatology 20070101 |
| The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. | Haematologica 20070101 |
| [Therapy sequence for renal cell carcinoma--new aspects!]. | Aktuelle Urologie 20070101 |
| Sorafenib: in advanced renal cancer. | Drugs 20070101 |
| Newly approved therapies for RCC and their effect on the standard of care. | Clinical advances in hematology & oncology : H&O 20070101 |
| Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. | Neuroendocrinology 20070101 |
| Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. | Medical hypotheses 20070101 |
| Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. | Anticancer research 20070101 |
| Rationale and clinical results of multi-target treatments in oncology. | The International journal of biological markers 20070101 |
| Renal cell cancer and sorafenib: skin toxicity and treatment outcome. | Tumori 20070101 |
| The role of targeted therapy in metastatic renal cell carcinoma. | TheScientificWorldJournal 20070101 |
| Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. | Journal of translational medicine 20070101 |
| [Effect of angiogenesis inhibitors on renal cell carcinoma]. | Magyar onkologia 20070101 |
| Targeted therapies for kidney cancer in urologic practice. | Urologic oncology 20070101 |
| Sorafenib: atypical cutaneous side effects. | European journal of dermatology : EJD 20070101 |
| [Angiogenesis targeting in renal carcinomas]. | Bulletin du cancer 20070101 |
| [New treatments for renal carcinoma]. | Anales del sistema sanitario de Navarra 20070101 |
| Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. | Oncology 20070101 |
| Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. | Journal of gastrointestinal cancer 20070101 |
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Cancer research 20061215 |
| Targeting von Hippel-Lindau pathway in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| Sorafenib for the treatment of advanced renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| Targeted therapy for metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210 |
| Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. | The Journal of pharmacology and experimental therapeutics 20061201 |
| New weapons to snuff out kidney cancer. | Nursing 20061201 |
| Molecularly targeted therapy in renal cell carcinoma: where do we go from here? | Expert review of anticancer therapy 20061201 |
| Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. | Expert review of anticancer therapy 20061201 |
| Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects. | Clinical genitourinary cancer 20061201 |
| Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. | Clinical genitourinary cancer 20061201 |
| Toxicities of antiangiogenic therapy in non-small-cell lung cancer. | Clinical lung cancer 20061201 |
| Raf kinases: oncogenesis and drug discovery. | International journal of cancer 20061115 |
| Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. | Clinical and experimental dermatology 20061101 |
| Sorafenib. | Current opinion in oncology 20061101 |
| Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). | The American journal of pathology 20061101 |
| Protein kinases as drug targets in cancer. | Current cancer drug targets 20061101 |
| Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. | Archives of dermatology 20061101 |
| Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress? | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101 |
| Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants. | Oncogene 20061026 |
| To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. | European journal of cancer (Oxford, England : 1990) 20061001 |
| Randomized discontinuation trial of sorafenib (BAY 43-9006). | Cancer biology & therapy 20061001 |
| Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001 |
| Problems with the randomized discontinuation design. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001 |
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nature reviews. Drug discovery 20061001 |
| [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma]. | Der Urologe. Ausg. A 20061001 |
| Speeding up cancer-drug development. | The Lancet. Oncology 20061001 |
| Molecular biology of renal cell carcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001 |
| A tale of two drugs. | Nature reviews. Drug discovery 20061001 |
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910 |
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. | British journal of cancer 20060904 |
| New treatment approaches in metastatic renal cell carcinoma. | Current opinion in urology 20060901 |
| Pharmacy benefit spending on oral chemotherapy drugs. | Journal of managed care pharmacy : JMCP 20060901 |
| Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. | Molecular cancer therapeutics 20060901 |
| Sorafenib (BAY 43-9006): review of clinical development. | Current clinical pharmacology 20060901 |
| Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. | Blood 20060815 |
| Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. | Seminars in oncology 20060801 |
| Current and future management of GIST. | Clinical advances in hematology & oncology : H&O 20060801 |
| Trials probe new agents for kidney cancer. | JAMA 20060712 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601 |
| Targeting Raf-kinase: molecular rationales and translational issues. | Annals of oncology : official journal of the European Society for Medical Oncology 20060601 |
| Molecular targeting therapy for renal cell carcinoma. | International journal of clinical oncology 20060601 |
| Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. | Clinical genitourinary cancer 20060601 |
| New therapeutic options for renal cell carcinoma. | Clinical advances in hematology & oncology : H&O 20060601 |
| Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. | Cancer chemotherapy and pharmacology 20060501 |
| Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. | Cytometry. Part B, Clinical cytometry 20060501 |
| Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. | Oncology (Williston Park, N.Y.) 20060501 |
| Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community. | Oncology (Williston Park, N.Y.) 20060501 |
| What's new in pancreatic cancer treatment pipeline? | Best practice & research. Clinical gastroenterology 20060401 |
| Mechanisms of hypertension associated with BAY 43-9006. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320 |
| Targeted therapy for metastatic renal cell carcinoma. | British journal of cancer 20060313 |
| Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? | European journal of cancer (Oxford, England : 1990) 20060301 |
| Sorafenib. | Expert opinion on pharmacotherapy 20060301 |
| VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. | Current oncology reports 20060301 |
| BAY 43-9006 inhibition of oncogenic RET mutants. | Journal of the National Cancer Institute 20060301 |
| BRAF is a therapeutic target in aggressive thyroid carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060301 |
| Multi-target inhibitors in non-small cell lung cancer (NSCLC). | Annals of oncology : official journal of the European Society for Medical Oncology 20060301 |
| Molecule of the month. Sorafenib. | Drug news & perspectives 20060301 |
| Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. | Clinical genitourinary cancer 20060301 |
| The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. | Cancer research 20060201 |
| [Progress in therapeutic strategy for renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060201 |
| Drug approval triggers debate on future direction for cancer treatments. | Nature reviews. Drug discovery 20060201 |
| Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. | FEBS letters 20060123 |
| Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060101 |
| New drugs: abatacept, sorafenib, and nelarabine. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| Treatment for advanced kidney cancer. | FDA consumer 20060101 |
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. | Methods in enzymology 20060101 |
| Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes. | ONS news 20060101 |
| Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses. | ONS news 20060101 |
| Report of the 2006 APhA House of Delegates. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. | Clinical genitourinary cancer 20051201 |
| Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. | Drugs of today (Barcelona, Spain : 1998) 20051201 |
| Update on angiogenesis inhibitors. | Current opinion in oncology 20051101 |
| Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. | The Journal of biological chemistry 20051021 |
| The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Oncogene 20051020 |
| Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20051001 |
| Raf: a strategic target for therapeutic development against cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920 |
| Promising systemic therapy for renal cell carcinoma. | Current treatment options in oncology 20050901 |
| Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. | Clinical lung cancer 20050901 |
| Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor. | Journal of neuro-oncology 20050901 |
| Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. | Clinical colorectal cancer 20050901 |
| Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? | Annals of internal medicine 20050816 |
| Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. | Current opinion in pharmacology 20050801 |
| Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. | BJU international 20050801 |
| Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050801 |
| Cutaneous side-effects of kinase inhibitors and blocking antibodies. | The Lancet. Oncology 20050701 |
| Multi-kinase inhibitors create buzz at ASCO. | Nature biotechnology 20050601 |
| Cancer. Encouraging results for second-generation antiangiogenesis drugs. | Science (New York, N.Y.) 20050527 |
| Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. | British journal of cancer 20050523 |
| Angiogenesis and lung cancer: prognostic and therapeutic implications. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510 |
| Clinical trials referral resource. | Oncology (Williston Park, N.Y.) 20050501 |
| Raf kinase as a target for anticancer therapeutics. | Molecular cancer therapeutics 20050401 |
| Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1. | Oncology (Williston Park, N.Y.) 20050401 |
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. | Cancer research 20050315 |
| Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. | Current oncology reports 20050301 |
| Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050210 |
| The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. | Anti-cancer drugs 20050201 |
| Raf kinase inhibitors in oncology. | Onkologie 20050201 |
| Cancer targets in the Ras pathway. | Cold Spring Harbor symposia on quantitative biology 20050101 |
| How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. | The Journal of endocrinology 20041101 |
| Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. | International journal of clinical pharmacology and therapeutics 20041101 |
| Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. | International journal of clinical pharmacology and therapeutics 20041101 |
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. | Cancer research 20041001 |
| Novel agents for the treatment of advanced kidney cancer. | Clinical advances in hematology & oncology : H&O 20041001 |
| Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925 |
| Kinase inhibition with BAY 43-9006 in renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040915 |
| B-RAF is a therapeutic target in melanoma. | Oncogene 20040819 |
| Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. | BMC cancer 20040101 |
| Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters? | International journal of clinical pharmacology and therapeutics 20031201 |
| Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. | International journal of clinical pharmacology and therapeutics 20031201 |
| Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20031201 |
| A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20031201 |
| Raf pathway inhibitors in oncology. | Current opinion in investigational drugs (London, England : 2000) 20031201 |
| Regulation of c-Raf-1: therapeutic implications. | Clinical advances in hematology & oncology : H&O 20030801 |
| BAY-43-9006 Bayer/Onyx. | Current opinion in investigational drugs (London, England : 2000) 20030601 |
| Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. | Clinical colorectal cancer 20030501 |
| ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. | International journal of clinical pharmacology and therapeutics 20021201 |
| Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. | International journal of clinical pharmacology and therapeutics 20021201 |
| Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics. | Hematology/oncology clinics of North America 20021001 |
| BAY 43-9006: early clinical data in patients with advanced solid malignancies. | Current pharmaceutical design 20020101 |
| BAY 43-9006: preclinical data. | Current pharmaceutical design 20020101 |